

T-CELL RECEPTOR VARIANT AGAINST mKRAS₇₋₁₆ G12V**CROSS-REFERENCE TO RELATED APPLICATIONS**

The present application claims the benefit of priority of EP Patent Application No. 23197810.7 filed 15 September 2023, the content of which is hereby incorporated by reference in its entirety for all purposes.

SEQUENCE LISTING

[001] This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference.

TECHNICAL FIELD OF THE INVENTION

[002] The present invention relates to a TCR polypeptide complex and/or a combination comprising a novel TCR characterized by its CDR sequences of the α chain variable region and the β chain variable region and by its antigenic specificity to (a) particular mutated KRAS epitope(s) or a fragment thereof presented in the context of a MHC class I molecule. The present invention further relates to a nucleic acid, a vector as well as a host cell comprising said nucleic acid or said vector. The present invention relates to a method for obtaining said TCR and said chimeric co-stimulatory receptor and to a pharmaceutical or diagnostic composition comprising the abovementioned. The present invention further relates to the abovementioned for use as a medicament or for use in a method of diagnosing, detecting, preventing, and/or treating cancer. Furthermore, the present invention relates to a method of detecting the presence of a cancer in a subject *in vitro*, by applying within said method the abovementioned, and the use of the abovementioned for generating modified lymphocytes and a kit.

BACKGROUND OF THE INVENTION

[003] T lymphocytes (or T cells) which form a part of the cell mediated immune system play a major role in the eradication of pathogens. T cells develop in the thymus and express T cell receptor molecules on their surface that allow the recognition of peptides presented on human leukocyte antigen (HLA) molecules which are expressed on nucleated cells (antigen presentation). Antigens of pathogens, i.e. foreign antigens presented by HLA molecules will elicit a powerful T cell response whereas self-antigens usually do not lead to a T cell response due to a negative selection of self-antigen specific T cells in the thymus during the development of such T cells. The immune system can thus discriminate between nucleated cells presenting

foreign- or self-antigens or self, but aberrant antigens and specifically target and eradicate infected cells via potent cytokine release and cellular cytotoxicity mechanisms of the T cells.

[004] The power of the immune system has been recognized as a promising tool for future cancer therapies. In the last decade, research has begun to exploit the unique properties of T cells by using adoptive cell transfer (ACT), which involves the administration of tumor infiltrating lymphocytes (TILs) which are patient-derived, expanded *ex vivo*. Although ACT has been shown to be a promising treatment for various types of cancer, its broad application as clinical treatment has been hampered by the need for custom isolation and characterization of tumor-specific T cells from each patient - a process that can be difficult and time-consuming but also often fails to yield high-avidity T cells (Xue et al., Clin Exp Immunol. 2005 February; 139(2): 167-172; Schmitt et al., Hum Gene Ther. 2009 November; 20(11): 1240-1248).

[005] The genetic transfer of tumor antigen-specific TCRs into primary T cells can overcome some of the current limitations of ACT, as it allows for the rapid generation of tumor-reactive T lymphocytes with defined antigen specificity even in immunocompromised patients. However, the identification of suitable T cell clones bearing TCRs that specifically recognize tumor antigens and exhibit the desired anti-tumor effects *in vivo* is still the topic of ongoing research.

[006] Tumors with Kirsten rat sarcoma (KRAS) mutations have been shown to create a tumor microenvironment (TME) that impairs immune cells in the TME and promotes tumor progression and immune escape. In the presence of KRAS mutations, increased levels of inflammatory cytokines necessary for tumorigenesis and progression have been observed in the TME. Under physiological conditions, the KRAS gene controls cell proliferation and survival. Activating mutations in the KRAS gene are highly prevalent oncogenic driver mutations in human cancers associated with tumorigenesis and aggressive tumor growth (Lee, J.K., et al., Precis. Onc., 2002, 6, 91). These mutations lead to the formation of so-called neoantigens, which are tumor-specific antigens (TSAs) that promote tumor growth and maintenance. KRAS has the highest mutation rate in a variety of frequently fatal solid cancers, including pancreatic ductal adenocarcinoma, endometrial cancer, non-small cell lung cancer, and colorectal cancer. The worldwide incidence of solid tumors harboring KRAS mutations is estimated to exceed 300,000 patients (Alexandrov LB, et al., Nature. 2020, 578(7793):94-101). The best-known mutations result from the substitution of only a single amino acid (G=glycine) at position 12 by aspartic acid (D), valine (V), or cysteine (C) (Yang Y, et al. J Clin Med. 2023;12(2):709). Considering that mutant KRAS (mKRAS) has been considered "undruggable" (Huang L, et al., Signal Transduct Target Ther. 2021;6(1):386), except for G12C mutations in some targeted therapies, novel and efficient treatment options for mKRAS tumors are urgently needed. It is the object of the present invention to comply with the needs set out above.

SUMMARY OF THE INVENTION

[007] This object is *inter alia* accomplished by a T-cell receptor (TCR) polypeptide complex and/or a combination comprising a novel TCR characterized by its Complementarity Determining Region (CDR) sequences of the α chain variable region and the β chain variable region, with the CDR3 which is the prime determinant of antigen recognition and specificity; and further comprising a chimeric co-stimulatory receptor. Such novel TCR is further characterized by its antigenic specificity to (a) particular mutated KRAS epitope(s) or a fragment thereof presented in the context of a major histocompatibility complex (MHC) class I molecule as outlined below. Such complex and/or combination is also expressed by a cell population comprising cells or a cell per se.

[008] Adoptive T Cell Receptor T cell (TCR-T) therapies have demonstrated efficacy in mKRAS-positive tumors but they do face major challenges to sustain function in solid tumor microenvironments (TME); tumor antigen levels and programmed death ligand 1 (PD-L1) expression strongly influence T cell function. PD L1 signaling to T cells via PD-1 limits proliferation, cytokine secretion and killing, while exhaustion is induced by repetitive TCR signaling in the absence of T cell co-stimulation. This holds particularly true for advanced stage disease. The inventors now found out that both impairments in TCR-T cells can be mitigated by co-expression of the high-affinity TCR of the present invention with a particular chimeric co-stimulatory receptor, such as for example a PD1-41BB costimulatory switch receptor (CSR), comprised of the extracellular domain of PD-1 at its N-terminus with the intracellular signaling domain of 4-1BB (CD137) at its C-terminus. By combining the novel TCR described in the present invention with a chimeric co-stimulatory receptor, such as PD1-41BB CSR (see **Figure 1**), TCR-T cell function in hostile TME was armored and enhanced. Further, it was demonstrated by the inventors that such TCR has additionally antigenic specificity to (an) particular mutated KRAS epitope or a fragment thereof presented in the context of a major histocompatibility complex (MHC) class I molecule. In detail, it has a specificity for the epitope comprising the amino acid sequence of SEQ ID NO: 1 (also referred to as mKRAS G12V - 10mer) meaning said TCR is capable of recognizing such epitope presented in the context of a MHC class I molecule in tumor cells (e.g., see **Figure 3**). Further, the inventors demonstrated that not only such TCR recognizes the particular peptide as defined above, but also a fragment thereof such as the epitope comprising the amino acid sequence of SEQ ID NO: 35 (also referred to as mKRAS G12V – 9mer) (e.g., see **Figure 4**). Additionally, the inventors have shown that the novel TCR is able to specifically recognize tumor cells expressing the target antigen comprising said epitope as defined herein (see **Figure 10**), demonstrating specificity of such TCR and its capacity to be activated and subsequently release IFN- γ in response to tumor cells expressing endogenous levels of mKRAS G12V.

[0009] In some aspects, the invention relates to a TCR polypeptide complex and/or a combination comprising: a) a TCR; and b) a chimeric co-stimulatory receptor, wherein the TCR comprises: i) an α chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 14; an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15; an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and ii) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2; a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4, wherein the TCR has antigenic specificity to (an) epitope(s) presented in the context of a MHC class I molecule, the epitope comprising the amino acid sequence of VVVGAVGVGK (SEQ ID NO: 1) or a fragment thereof (e.g., SEQ ID NO: 35).

[0010] In some aspects, the invention relates to fusion proteins comprising (a) an extracellular domain containing a polypeptide derived from PD-1 or CD40L at its N-terminus; (b) a transmembrane domain (e.g., derived from PD-1); and (c) an intracellular domain containing a polypeptide derived from 4-1BB or CD28 at its C-terminus. Also, fusion proteins with CD28 at the N-terminus and CD40L at the C-terminus are envisaged.

[0011] In some aspects, the invention relates to a cell population comprising cells or a cell expressing: a) a TCR; and b) a chimeric co-stimulatory receptor, wherein the TCR comprises: i) an α chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 14; an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15; an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16; and ii) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2; a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4, wherein the TCR has antigenic specificity to (an) epitope(s) presented in the context of a MHC class I molecule, the epitope comprising the amino acid sequence of VVVGAVGVGK (SEQ ID NO: 1) or a fragment thereof (e.g., SEQ ID NO: 35).

[0012] In some aspects, the invention relates to a nucleic acid comprising a nucleotide sequence encoding the TCR as mentioned above and defined herein and a nucleotide sequence encoding the chimeric co-stimulatory receptor as mentioned above and defined herein.

[0013] In some aspects, the invention relates to a vector comprising the nucleic acid as mentioned above and defined herein.

[0014] In some aspects, the invention relates to a host cell comprising the nucleic acid or the vector as mentioned above and defined herein.

[0015] In some aspects, the present invention also relates to a method for obtaining the TCR and the chimeric co-stimulatory receptor as mentioned above, comprising (i) incubating the host cell as defined above under conditions causing expression of said TCR and of said

chimeric co-stimulatory receptor; and (ii) purifying said TCR and said chimeric co-stimulatory receptor.

[0016] In some aspects, the invention relates to a pharmaceutical or diagnostic composition comprising one or more of: (i) the complex and/or the combination; (ii) the cell population or the cell, (iii) the nucleic acid; (iv) the vector; and/or (v) the host cell as mentioned above and defined herein; and, optionally, pharmaceutically excipient(s).

[0017] In some aspects, the present invention relates to the complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition as mentioned above and defined herein for use as a medicament and/or for use in therapy.

[0018] In some aspects, the present invention relates to the complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition as mentioned above and defined herein for use in a method of detecting, diagnosing, prognosing, preventing and/or treating cancer.

[0019] In some aspects, the present invention also relates to a method of detecting the presence of a cancer in a subject *in vitro*, comprising (a) contacting a sample obtained from a subject and comprising one or more cells with (i) the complex and/or the combination; (ii) the cell population or the cell, (iii) the nucleic acid; (iv) the vector; (v) the host cell; and/or (vi) the pharmaceutical composition as mentioned above and defined herein, thereby forming a complex, and (b) detecting the complex, wherein detection of the complex is indicative of the presence of the cancer in the subject.

[0020] In some aspects, the present invention also relates to the use of the complex and/or the combination, and/or the cell population or the cell, the nucleic acid and/or the vector as mentioned above and defined herein for generating modified lymphocytes.

[0021] In some aspects, the present invention relates to a kit comprising the complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell, and/or the pharmaceutical or diagnostic composition as mentioned above and defined herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the drawings, in which:

[0023] **Fig. 1** shows retroviral transduction induces high and robust transgenic TCR and PD1-41BB CSR expression. TCR in combination with PD1-41BB (TCR + PD1-41BB) was expressed into CD8⁺ T cells by retroviral transduction. Untransduced CD8⁺ T cells (UT) were prepared in the same manner and used as controls. After transduction, CD8⁺ T cells were enriched using anti-CD8, anti-TCR Cβ1 and anti-PD1 antibodies by fluorescence-activated cell sorting (FACS). To assess transduction efficiency and expression levels of the transgenes, T

cell samples were stained with anti-TCR C β 1, anti-PD1 and anti-CD8 antibodies and analyzed by flow cytometry. Populations shown are pre-gated on live single CD8⁺ T cells. One representative experiment is shown.

[0024] Fig. 2 shows high and exclusive mKRAS₇₋₁₆ G12V (10-mer) multimer binding. After enrichment and rapid expansion protocol, TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) were stained with either mKRAS₇₋₁₆ G12V (10-mer) HLA-A*11:01 multimer and analyzed by flow cytometry. Untransduced CD8⁺ T cells (UT) were stained and analyzed in parallel as internal controls. Populations shown are pre-gated on live single cells. One representative experiment is shown.

[0025] Fig. 3 shows that T cells exhibit exclusive mKRAS₇₋₁₆ G12V specificity with no KRAS wild-type recognition. TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) were co-cultured with PDL1-transduced K562 cells expressing transgenic HLA-A*11:01-encoding molecules (K562_A11_PDL1) loaded with either mKRAS₇₋₁₆ G12V peptide or KRAS₇₋₁₆ wild-type (WT) peptide at high concentration (10⁻⁵M). Additionally, CD8⁺ T cell samples were also co-cultured with K562_A11_PDL1 cells transfected with either ivtRNA encoding a fragment of mKRAS G12V gene (~402 bp) or ivtRNA encoding a fragment of KRAS G12 wild-type gene (~402 bp). K562_A11_PDL1 cells unloaded as well as electroporated (EP) with water served as target controls. Untransduced (UT) CD8⁺ T cells were included as negative controls. After 20 hours (h) of co-culture, an ELISA was performed to evaluate IFN- γ secretion by T cells. The mean value of duplicates is shown with standard deviations. One representative experiment is shown.

[0026] Fig. 4 shows that T cells exhibit high peptide sensitivity for mKRAS₇₋₁₆ G12V (10-mer) epitope. TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) tested in a co-culture experiment using K562_A11_PDL1 cells loaded with graded amounts of either mKRAS₇₋₁₆ G12V (10-mer) peptide or mKRAS₈₋₁₆ G12V (9-mer) peptide (10⁻⁵ M to 10⁻¹² M) for direct comparison of peptide sensitivity for the two peptide length variants. After 20 h of co-culture, an ELISA was performed to evaluate IFN- γ secretion by T cells. Maximal IFN- γ release per effector cell sample was set to 100%. Based on this, the relative IFN- γ release was calculated. A nonlinear regression analysis was used to determine EC50 values (peptide concentration needed for half maximal relative IFN- γ secretion) for TCR + PD1-41BB-transduced CD8⁺ T cells in response to the two mKRAS G12V peptide length variants. One representative experiment is shown.

[0027] Fig. 5 shows peptide-specific restriction to three different HLA-A*11 subtypes. CD8⁺ T cells expressing either no transgenic TCR (UT) or the combination of TCR and PD1-41BB CSR (TCR + PD1-41BB) were co-cultured with a set of HLA-transduced K562 cell samples. Each K562 sample expressed one of the following transgenic HLA molecules: HLA-A*11:01, HLA-A*11:02, HLA-A*11:03, HLA-A*11:04. Each HLA-transduced K562 sample was tested after

mKRAS₇₋₁₆ G12V peptide loading (10^{-5} M). IFN- γ release was evaluated by ELISA 20 h after setting up the co-culture. The mean value of duplicates is shown with standard deviations. One representative experiment is shown.

[0028] Fig. 6 shows that there are no signs of target peptide-independent cross-recognition of global frequent HLA allotypes. TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) and untransduced (UT) CD8⁺ T cells were co-cultured with two cellular libraries. The first library comprised 70 lymphoblastoid cell lines (LCLs, LCL library, **Figure 6A**) and the second library comprised 31 K562 cell samples transduced with individual HLA molecules (K562 library, **Figure 6B**). K562_A11 cells loaded with mKRAS₇₋₁₆ G12V peptide (10^{-5} M) served as internal positive control (pos control). IFN- γ secretion was evaluated by ELISA 20 h after setting up the co-culture. The mean value of duplicates is shown with standard deviations. One representative experiment is shown.

[0029] Fig. 7 shows the successful de-risking of potential peptide off-target toxicity. Mismatched peptides, which were identified as recognized by TCR +PD1-41BB in a screening assay performed with peptide loading of target cells at high concentrations (10^{-6} M), were tested for their potential to induce IFN- γ release when translated from ivtRNA and endogenously processed and presented by K562_A11_PDL1 cells. Midi-gene fragments were designed spanning the respective peptide-coding region and linked to GFP reporter gene. Co-culture experiments were established by using TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) and mismatched peptide (MM) midi-gene fragment ivtRNA-transfected K562_A11_PDL1 target cells. Target cells transfected with mKRAS₇₋₁₆ G12V midi-gene fragment ivtRNA (fragment spanning mKRAS₇₋₁₆ G12V peptide-coding region and linked to GFP) were included as positive control. Water electroporation (water EP) of target cells served as negative control. The transfection efficiency of target cells was evaluated by flow cytometry analyzing GFP signals (**Figure 7A**). IFN- γ secretion was evaluated by ELISA 20 h after setting up the co-culture. The mean value of duplicates is shown with standard deviations. One representative experiment is shown (**Figure 7B**).

[0030] Fig. 8 shows that no signs of off-target toxicity were identified using a panel of healthy cell samples. HLA-A*11:01-positive primary healthy cells and induced pluripotent stem cell (iPS)-derived cell lines representing essential organs were tested for recognition by TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB). Untransduced (UT) CD8⁺ T cells served as internal controls. Target cells loaded with mKRAS₇₋₁₆ G12V peptide (10^{-5} M) were included as internal positive controls. IFN- γ secretion was evaluated by ELISA 20 h after setting up the co-culture. The mean value of duplicates is shown with standard deviations. One representative experiment is shown. Human Renal Cortical Epithelial Cells (HRCEpC), Normal Human Lung Fibroblasts (NHLF), Human Cardiac Fibroblasts (HCF-c), Human Cardiac Fibroblasts-Atrial (NHCF-A).

[0031] Fig. 9 shows that TCR-transduced T cells produce high and specific IFN- γ secretion in response to tumor cells. Tumor cell lines derived from various indications expressing either mKRAS G12V at different levels (DAN-G, SW527, NCI-H441, SW480) or KRAS wild-type (DU145, Mel624.38) were selected for this co-culture experiment. To obtain robust and stable PDL1 expression, all selected tumor cell lines were transduced with PDL1 and tested both with and without PDL1 transduction. The co-culture experiment was set up by using the described tumor cell lines and TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB). Untransduced (UT) CD8⁺ T cells served as negative control. IFN- γ secretion was assessed 20 h after setting up the co-culture. The mean value of duplicates is shown with standard deviations. One representative experiment is shown.

[0032] Fig. 10 shows that a strong and specific cytotoxic response occurs against tumor cells even after multiple tumor challenges. Tumor cell lines derived from various indications expressing either mKRAS G12V at different levels (DAN-G, SW527, NCI-H441, SW480) or only KRAS wild-type (DU145, Mel624.38) were selected for this co-culture experiment. To obtain robust and stable PDL1 expression, all selected tumor cell lines were transduced with PDL1 and tested both with and without PDL1 transduction. All tumor cells stably expressed a red fluorescent protein for cell tracking. The described tumor cell lines were co-cultured with either TCR + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) or untransduced (UT) CD8⁺ T cells. Cytotoxicity mediated by T cells was determined by reduction in the absolute number of red fluorescent tumor cells over time using a live-cell imaging system. Absolute cell numbers of red fluorescent tumor cells per well at every point of measurement were calculated using the IncuCyte® software. Cell numbers (target cells/well) are shown as mean of three replicates. One representative experiment is shown. (Figure 10A).

[0033] To test T cell performance in a challenging environment, TCR1 + PD1-41BB-transduced CD8⁺ T cells (TCR + PD1-41BB) were co-cultured with 3-dimensional (3D) tumor cell spheroids and multiple challenges with fresh tumor cell spheroids were performed by transferring the tumor cells to the co-culture plates. Hence, red fluorescent mKRAS G12V-positive tumor cells (DAN-G and NCI-H441) were selected as target cells for this assay. These cell lines were tested both with and without PDL1 transduction. PDL1-transduced tumor cells served to further challenge T cells and to assess cytotoxic activity mediated by TCR + PD1-41BB-transduced CD8⁺ T cells in the presence of high levels of PDL1. Cytotoxicity mediated by T cells was determined by the reduction of red fluorescence signal over time using a live-cell imaging system. Red fluorescence integrated intensity (Red Calibrated Unit (RCU)/ $\mu\text{m}^2/\text{image}$) is shown at every point of measurement as mean of three replicates which was calculated using the IncuCyte® software. One representative experiment is shown. (Figure 10B).

[0034] Fig. 11 shows a higher polyfunctionality of T cells co-expressing the transgenic TCR and PD1-41BB CSR compared to T cells expressing only the transgenic TCR. TCR-transduced CD8⁺ T cells with (TCR+PD1-41BB) and without (TCR) co-expression of PD1-41BB CSR were analyzed after 24 hours of co-culture with mKRAS G12V-positive DAN-G_A11_PD-L1 tumor cells using single-cell proteomic analysis of a panel of 32 secreted cytokines, chemokines, and cytotoxic molecules (IsoLight® technology). Cells secreting 2 or more cytokines were considered polyfunctional (**Figure 11A**). Polyfunctional Strength Index (PSI) of the displayed samples was defined as the number of T cells secreting more than 2 effector molecules per cell (polyfunctional T cells) multiplied by mean fluorescence intensity (MFI) of the proteins secreted by the respective cells and categorized in proteins associated with effector, stimulatory, chemo-attractive, regulatory and inflammatory properties (**Figure 11B**).

[0035] The TCR of the invention can also be referred to in the Figures as “TCR6 PD1-41BB”.

DETAILED DESCRIPTION OF THE INVENTION

[0036] TCR and CDRs:

[0037] The term “TCR” as used herein includes native TCRs as well as TCR variants, fragments and constructs as defined herein. The term thus includes heterodimers comprising TCR alpha and beta chains as well as multimers and single chain constructs; optionally comprising further domains and/or moieties.

[0038] In its native form, the TCR exists as a complex of several proteins on the surface of T cells. The T cell receptor is composed of two (separate) protein chains, which are produced from the independent T cell receptor alpha and beta (TCR α and TCR β) genes and are called alpha (α -) and beta (β -) chains. Each chain of the TCR possesses one N-terminal immunoglobulin-like (Ig)-variable (V) domain/region, one Ig-constant-like (C) domain/region, a transmembrane/cell membrane-spanning region anchoring the chain in the plasma membrane, and a short cytoplasmic tail at the C-terminal end.

[0039] Antigen specificity is conferred by the variable regions of the alpha and beta chain. Both variable regions of the TCR alpha chain and beta chain comprise three hypervariable or complementarity determining regions (CDR1alpha/beta, CDR2alpha/beta and CDR3 alpha/beta) surrounded by framework (FR) regions. CDR3 is the prime determinant of antigen recognition and specificity (i.e. the ability to recognize and interact with a specific antigen), whereas CDR1 and CDR2 mainly interact with the MHC molecule presenting the antigenic peptide.

[0040] The TCR of the present invention is characterized by comprising i) an α chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 16; and/or ii) a β chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 4. It is also comprised herein a TCR comprising an α chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 16. It is also comprised herein a TCR comprising an α chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 4. The present invention also comprise the TCR as defined herein being characterized as comprising i) an α chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 16 and ii) a β chain CDR3 comprising an amino acid sequence having at least 80 %, such as

at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 4.

[0041] It is envisaged that the CDR3 of the present invention can in principle be combined with any of the CDR1 depicted in SEQ ID NO: 14 and/or 2 and/or with any of the CDR2 depicted in SEQ ID NO: 15 and/or 3, preferably provided that the TCR retains its ability to recognize its epitope as defined elsewhere herein, to a similar, the same or even a higher extent as the TCR evaluated in the Examples.

[0042] The TCR of the invention may further be provided in "isolated" or "substantially pure" form. "Isolated" or "substantially pure" when used herein means that the TCR have been identified separated and/or recovered from a component of its production environment, such that the "isolated" TCR is free or substantially free of other contaminant components from its production environment that might interfere with its therapeutic or diagnostic use. Contaminant components may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. "Isolated" TCR will thus be prepared by at least one purification step removing or substantially removing these contaminant components. The aforementioned definition is equally applicable to "isolated" polynucleotides/nucleic acids, *mutatis mutandis*.

[0043] The TCR of the present invention as defined herein may further be characterized as comprising at least one (e.g. 1, 2, 3, or 4) of the following: i) an α chain CDR 1 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 14; ii) an α chain CDR2 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 15; iii) a β chain CDR1 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 2; and/or iv) a β chain CDR2 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 3.

[0044] Thus, the present invention may also comprise the TCR as defined above being further characterized as comprising an α chain CDR 1 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 14. Thus, the present invention may also comprise the TCR as defined above being further characterized as comprising an α chain CDR 2 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 15. Thus, the present invention may also comprise the TCR as defined above being further characterized as comprising a β chain CDR1 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,

98, 99% or even 100% identity to SEQ ID NO: 2. Thus, the present invention may also comprise the TCR as defined above being further characterized as comprising a β chain CDR2 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 3.

[0045] The present invention may also comprise the TCR as defined herein further being characterized as comprising i) an α chain CDR 1 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 14; ii) an α chain CDR2 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 15; and iii) an α chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein further being characterized as comprising i) a β chain CDR1 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 2; ii) a β chain CDR2 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 3; and iii) a β chain CDR3 comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity to SEQ ID NO: 4.

[0046] The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative or highly conservative amino acid substitutions as defined herein, preferably corresponding to position 1, 2, 3, 4, 5 and/or 6 of SEQ ID NO: 14; position 1, 2, 3, 4, 5 and/or 6 of SEQ ID NO: 15; position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and/or 12 of SEQ ID NO: 16; position 1, 2, 3, 4 and/or 5 of SEQ ID NO: 2; position 1, 2, 3, 4, 5 and/or 6 of SEQ ID NO: 3; and/or position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and/or 13 of SEQ ID NO: 4.

[0047] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative or highly conservative amino acid substitutions as defined herein corresponding to position 1, 2, 3, 4, 5, and/or 6 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at

least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 14.

[0048] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 14. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96,

97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 14.

[0049] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative or conservative amino acid substitutions as defined herein corresponding to position 1, 2, 3, 4, 5, and/or 6 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 15.

[0050] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87,

88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 15. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 15.

[0051] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative or conservative amino acid substitutions as defined herein corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and/or 12 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or

even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 7 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 8 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 9 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 10 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 11 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 12 of SEQ ID NO: 16.

[0052] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as

defined herein corresponding to position 4 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 7 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 8 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 9 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 10 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 11 of SEQ ID NO: 16. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 12 of SEQ ID NO: 16.

[0053] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative or conservative amino acid substitutions as defined herein corresponding to position 1, 2, 3, 4, and/or 5 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 2. The present invention may also

comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 2.

[0054] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 2. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 2.

[0055] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative or conservative amino acid substitutions as defined herein corresponding to position 1, 2, 3, 4, 5

and/or 6 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 3.

[0056] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 3. The present invention may also

comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 3. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 3.

[0057] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative or conservative amino acid substitutions as defined herein corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, and/or 13 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 7 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%,

such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 8 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 9 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 10 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 11 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 12 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises conservative amino acid substitutions as defined herein corresponding to position 13 of SEQ ID NO: 4.

[0058] The present invention may also comprise the TCR as defined herein and further being characterized, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 1 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 2 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 3 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 4 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises

highly conservative amino acid substitutions as defined herein corresponding to position 5 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 6 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 7 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 8 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 9 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 10 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 11 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 12 of SEQ ID NO: 4. The present invention may also comprise the TCR as defined herein, wherein the at least 80%, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or even 100% identity comprises highly conservative amino acid substitutions as defined herein corresponding to position 13 of SEQ ID NO: 4.

[0059] In a preferred embodiment, the present invention comprises the TCR as defined herein, further comprising i) an α chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 14; ii) an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15; iii) an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16; iv) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2; v) a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; and vi) a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4 (see **Table 2**).

[0060] Complete variable region:

[0061] The present invention may further provide a TCR comprising a TCR α chain variable region and/or a TCR β chain variable region. Said α and β chain variable region sequences are also shown in **Table 2**. The present invention may further comprise the TCR as defined herein comprising i) an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 20; and/or ii) an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 8. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 20. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 8. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 85 % identity to SEQ ID NO: 20. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 85 % identity to SEQ ID NO: 8. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 90 % identity to SEQ ID NO: 20. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 90 % identity to SEQ ID NO: 8. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 95 % identity to SEQ ID NO: 20. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 95 % identity to SEQ ID NO: 8. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 98 % identity to SEQ ID NO: 20. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 98 % identity to SEQ ID NO: 8.

[0062] In a more preferred embodiment, the present invention comprises the TCR as defined herein, further comprising i) an α chain variable region comprising the amino acid sequence of SEQ ID NO: 20, and/or ii) a β chain variable region comprising the amino acid sequence of SEQ ID NO: 8.

[0063] Constant region:

[0064] The TCR may further comprise a constant (C) region in its α and/or β chain. The constant region can be a human constant region or derived from another species, yielding a "chimeric" TCR. For instance, human alpha and/or beta chains can be replaced by their murine

counterparts ("murinization") which has been found to enhance surface expression of human TCRs by supporting preferential pairing of the TCR α and β chains, and a more stable association with the CD3 co-receptor. Thus, the present invention may comprise the TCR as defined herein further comprising a (minimally) murinized constant region in its α and/or β chain. The present invention may further comprise the TCR as defined herein comprising i) an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 22; and/or ii) an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 10. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 22. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 10. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 85 % identity to SEQ ID NO: 22. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 85 % identity to SEQ ID NO: 10. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 90 % identity to SEQ ID NO: 22. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 90 % identity to SEQ ID NO: 10. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 95 % identity to SEQ ID NO: 22. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 95 % identity to SEQ ID NO: 10. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 98 % identity to SEQ ID NO: 22. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 98 % identity to SEQ ID NO: 10.

[0065] In a more preferred embodiment, the present invention comprises the TCR as defined herein, further comprising i) an α chain constant region comprising the amino acid sequence of SEQ ID NO: 22, and/or ii) a β chain constant region comprising the amino acid sequence of SEQ ID NO: 10 (see **Table 2**).

[0066] Alpha and beta chains:

[0067] The present invention may further comprise the TCR as defined herein comprising i) an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88,

89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 24; and/or ii) an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 12. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 24. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 80 %, such as at least 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or even 100% identity to SEQ ID NO: 12. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 85 % identity to SEQ ID NO: 24. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 85 % identity to SEQ ID NO: 12. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 90 % identity to SEQ ID NO: 24. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 90 % identity to SEQ ID NO: 12. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 95 % identity to SEQ ID NO: 24. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 95 % identity to SEQ ID NO: 12. Thus, the present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 98 % identity to SEQ ID NO: 24. The present invention may further comprise the TCR as defined herein comprising an amino acid sequence having at least 98 % identity to SEQ ID NO: 12.

[0068] In a most preferred embodiment, the present invention comprises the TCR as defined herein, further comprising i) an α chain comprising the amino acid sequence of SEQ ID NO: 24; and/or ii) a β chain comprising the amino acid sequence of SEQ ID NO: 12 (see **Table 2**).

[0069] As used herein the term “sequence identity” indicates the extent to which two (nucleotide or amino acid) sequences have identical residues at the same positions in an alignment, and is often expressed as a percentage. Preferably, identity is determined over the entire length of the sequences being compared. Thus, two copies of exactly the same sequence have 100% identity, but sequences that are less highly conserved and have deletions, additions, or replacements, may have a lower degree of identity. Those skilled in the art will recognize that several algorithms are available for determining sequence identity using standard parameters, for example Blast (Altschul, et al. (1997) *Nucleic Acids Res.* 25:3389-3402), Blast2 (Altschul, et al. (1990) *J. Mol. Biol.* 215:403-410), Smith-Waterman (Smith, et al. (1981) *J. Mol. Biol.* 147:195-197) and ClustalW.

[0070] Epitope:

[0071] KRAS, also referred to as GTPase KRas, V-Ki-Ras2 Kirsten rat sarcoma viral oncogene, or KRAS2, is a member of the small GTPase superfamily. There are two transcript variants of KRAS: KRAS variant A and KRAS variant B. Hereinafter, references to "KRAS" (mutated or unmutated) refer to both variant A and variant B, unless specified otherwise. Without being bound to a particular theory or mechanism, it is believed that, when mutated, KRAS may be involved in signal transduction early in the oncogenesis of many human cancers. A single amino acid substitution may activate the mutation. When activated, mutated KRAS binds to guanosine-5'-triphosphate (GTP) and converts GTP to guanosine 5'-diphosphate (GDP). The mutated KRAS protein product may be constitutively activated. Mutated KRAS protein may be expressed in any of a variety of human cancers such as, for example, pancreatic (e.g., pancreatic carcinoma), colorectal, lung (e.g., lung adenocarcinoma), endometrial, ovarian (e.g., epithelial ovarian cancer), and prostate cancers.

[0072] The TCR of the present invention may further have antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 (VVVGAVGVGK). Such epitope is mutated and refers to a mutated KRAS peptide which generally corresponds to positions 7-16 of the unmutated, wild type (WT) KRAS protein amino acid sequence of SEQ ID NO: 37 with the exception that for SEQ ID NO: 1, the glycine at position 12 of SEQ ID NO: 37 (which refers to position 6 in SEQ ID NO: 1) is substituted with valine, respectively. The mutated KRAS amino acid sequence SEQ ID NO: 1 is also referred to herein as "mKRAS G12V – 10mer." The TCR of the present invention may not have antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 34.

[0073] In a further embodiment of the invention, the TCR may further have antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of a fragment of the amino acid sequence of SEQ ID NO: 1, or a variant of the amino acid sequence of SEQ ID NO: 1 comprising one or more (e.g. one or two) conservative amino acid substitutions (preferably corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9 and/or 10 of SEQ ID NO: 1).

[0074] A "fragment thereof" as used herein, refers to a part of the mutated KRAS peptide (according to SEQ ID NO: 1) having one or more amino acids absent from the amino and/or carboxyl terminus of the mutated KRAS peptide comprising or consisting of the amino acid sequence of SEQ ID NO: 1. The fragment as defined herein may also comprise the mutated epitope comprising the amino acid sequence of VVGAVGVGK (SEQ ID NO: 35). Such mutated epitope refers to a mutated KRAS peptide which generally corresponds to positions 8-16 of

the unmutated, wild type (WT) KRAS protein amino acid sequence of SEQ ID NO: 37 with the exception that for SEQ ID NO: 35, the glycine at position 12 of SEQ ID NO: 37 (which refers to position 5 in SEQ ID NO: 35) is substituted with valine, respectively. The mutated KRAS amino acid sequence SEQ ID NO: 35 is also referred to herein as "mKRAS G12V – 9mer." The TCR of the present invention may not have antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 36.

[0075] The term "variant" may refer to a polypeptide having specific activity as described herein comprising an alteration, i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several, e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10, etc.) positions. A "variant thereof" as used herein, may particularly comprise the mutated KRAS peptide as mentioned above with one or more positions being substituted. A substitution means replacement of the amino acid occupying a position with a different amino acid; a deletion means removal of the amino acid occupying a position; and an insertion means adding an amino acid adjacent to and immediately following the amino acid occupying a position.

[0076] As used herein, "silent" mutations mean base substitutions within a nucleic acid sequence which do not change the amino acid sequence encoded by the nucleic acid sequence. "Conservative or equivalent" substitutions (or mutations) mean substitutions as listed as "Exemplary Substitutions" in Table 1 below. "Highly conservative" substitutions as used herein mean substitutions as shown under the heading "Preferred Substitutions" in **Table 1** below.

[0077] Table 1: Amino acid substitutions.

Original	Exemplary Substitutions	Preferred Substitutions
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; asp, lys; arg	gln
Asp (D)	glu; asn	glu
Cys (C)	ser; ala	ser
Gln (Q)	asn; glu	asn
Glu (E)	asp; gln	asp
Gly (G)	ala	ala
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe;	leu
Leu (L)	norleucine; ile; val; met; ala;	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala; tyr	tyr
Pro (P)	ala	ala
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr; phe	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe; ala;	leu

[0078] The term "amino acid" or "amino acid residue" typically refers to an amino acid having its art recognized definition such as an amino acid selected from the group consisting of: alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine (Cys or C); glutamine (Gln or Q); glutamic acid (Glu or E); glycine (Gly or G); histidine (His or H); isoleucine (Ile or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V), although modified, synthetic, or rare amino acids may be used as desired. For ease of reference, polypeptide variants (or mutants) of the invention may be referred to by the use of the following nomenclature: original amino acid(s): position(s): substituted amino acid(s). According to this nomenclature, for instance the substitution of G (glycine) for V (valine) in position 12 can be shown as "G12V".

[0079] The term "position" when used in accordance with the disclosure means the position of either an amino acid within an amino acid sequence depicted herein or the position of a nucleotide within a nucleic acid sequence depicted herein. The term "corresponding" as used herein also includes that a position is not only determined by the number of the preceding nucleotides/amino acids, but is rather to be viewed in the context of the circumjacent portion of the sequence. Accordingly, the position of a given amino acid or nucleotide in accordance

with the disclosure may vary due to deletion or addition of amino acids or nucleotides elsewhere in the sequence. Thus, when a position is referred to as a “corresponding position” in accordance with the disclosure it is understood that nucleotides/amino acids may differ in terms of the specified numeral but may still have similar neighboring nucleotides/amino acids. In order to determine whether an amino acid residue (or nucleotide) in a given sequence corresponds to a certain position in the amino acid sequence of a “parent” amino acid/nucleotide sequence, the skilled person can use means and methods well-known in the art, e.g., sequence alignments, either manually or by using computer programs such as exemplified herein.

[0080] In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 35.

[0081] In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising one conservative amino acid substitution, preferably corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9 and/or 10 of SEQ ID NO: 1. In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising one highly conservative amino acid substitution, preferably corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9 and/or 10 of SEQ ID NO: 1. In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising one conservative amino acid substitution corresponding to position 1, 2, 3, 4, 5, 7, 8, 9 and/or 10 of SEQ ID NO: 1. In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising one highly conservative amino acid substitution corresponding to position 1, 2, 3, 4, 5, 7, 8, 9 and/or 10 of SEQ ID NO: 1.

[0082] In a further embodiment of the invention, the TCR may further have antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising two conservative amino acid substitutions, preferably corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9 and/or 10 of SEQ ID NO: 1. In a further embodiment of the invention, the TCR may further have antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising two highly conservative amino acid substitutions, preferably corresponding to position 1, 2, 3, 4, 5, 6, 7,

8, 9 and/or 10 of SEQ ID NO: 1. In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising two conservative amino acid substitutions corresponding to position 1, 2, 3, 4, 5, 7, 8, 9 and/or 10 of SEQ ID NO: 1. In a further embodiment of the invention, the TCR may have further antigenic specificity to an epitope presented in the context of a MHC class I molecule, the epitope comprising or consisting of the amino acid sequence of SEQ ID NO: 1 comprising two highly conservative amino acid substitutions corresponding to position 1, 2, 3, 4, 5, 7, 8, 9 and/or 10 of SEQ ID NO: 1.

[0083] The term "antigenic specificity," as used herein, means that the TCR can specifically bind to and immunologically recognize mutated target, e.g., mutated KRAS peptide as defined herein, with high avidity. Effector host cells expressing the TCR as described herein are envisaged to bind to their antigenic target (i.e. the epitope as defined herein) with a high functional avidity. The term "functional avidity" refers to the capability of TCR expressing cells (in particular T-cells expressing native TCRs as described herein) to respond *in vitro* to a given concentration of a ligand and is thought to correlate with the *in vivo* effector capacity of TCR expressing cells. By definition, TCR expressing cells with high functional avidity respond in *in vitro* tests to very low antigen doses, while such cells of lower functional avidity require higher amounts of antigen before they mount an immune response similar to that of high-avidity TCR expressing cells. The functional avidity can be therefore considered as a quantitative determinant of the activation threshold of a TCR expressing cell. It is determined by exposing such cells *in vitro* to different amounts of cognate antigen. TCR expressing cells with high functional avidity respond to low antigen doses. For example, a TCR expressing cell will typically be considered to bind with "high" functional avidity to its antigenic target (having antigenic specificity for the mutated epitope) if a) it secretes at least about 200 pg/mL or more (e.g., 200 pg/mL or more, 300 pg/mL or more, 400 pg/mL or more, 500 pg/mL or more, 600 pg/mL or more, 700 pg/mL or more, 1000 pg/mL or more, 5,000 pg/mL or more, 7,000 pg/mL or more, 10,000 pg/mL or more, or 20,000 pg/mL or more, or a range defined by any two of the foregoing values) of interferon gamma (IFN-gamma) upon co-culture with antigen-negative HLA-A*11 expressing target cells loaded with a low concentration of the mutated target peptide ranging from about 10^{-5} to about 10^{-11} M (i.e., about 0.05 ng/mL to about 5 ng/mL, 0.05 ng/mL, 0.1 ng/mL, 0.5 ng/mL, 1 ng/mL, or 5 ng/mL or a range defined by any two of the foregoing values), or (b) antigen-negative HLA-A11⁺ target cells into which a nucleotide sequence encoding the mutated target has been introduced such that the target cell expresses the mutated target. Cells expressing the TCR of the invention may also secrete IFN- γ upon co-culture with antigen-negative HLA-A11⁺ target cells pulsed with higher concentrations of mutated target peptide.

[0084] Other methods to determine specific binding of the TCR of the invention may include the ⁵¹Cr-release assay described by Gertner-Dardenne et al. J Immunol 188(9): 4701-4708, CD107a/b mobilization described by Leisegang et al., Clin. Cancer Res 2010. 16: 2333–2343 and peptide:MHC multimer binding analyses described by Wilde et al., J Immunol 2012; 189:598-605.

[0085] Alternatively or additionally, a TCR may be considered to have "antigenic specificity" for a mutated target if T cells expressing the TCR secrete at least twice as much IFN-γ upon co-culture with (a) antigen-negative HLA-A11⁺ target cells pulsed with a low concentration of mutated target peptide or (b) antigen-negative HLA-A11⁺ target cells into which a nucleotide sequence encoding the mutated target has been introduced such that the target cell expresses the mutated target as compared to the amount of IFN-γ expressed by a negative control. The negative control may be, for example, (i) T cells expressing the TCR, co-cultured with (a) antigen-negative HLA-A11⁺ target cells pulsed with the same concentration of an irrelevant peptide (e.g., some other peptide with a different sequence from the mutated target peptide) or (b) antigen-negative HLA-A11⁺ target cells into which a nucleotide sequence encoding an irrelevant peptide has been introduced such that the target cell expresses the irrelevant peptide, or (ii) untransduced T cells (e.g., derived from PBMC, which do not express the TCR) co-cultured with (a) antigen-negative HLA-A11⁺ target cells pulsed with the same concentration of mutated target peptide or (b) antigen-negative HLA-A11⁺ target cells into which a nucleotide sequence encoding the mutated target has been introduced such that the target cell expresses the mutated target. IFN-γ secretion may be measured by methods known in the art such as, for example, enzyme-linked immunosorbent assay (ELISA).

[0086] Alternatively or additionally, a TCR may be considered to have "antigenic specificity" for a mutated target if at least twice as many of the numbers of T cells expressing the TCR secrete IFN-γ upon co-culture with (a) antigen-negative HLA-A11⁺ target cells pulsed with a low concentration of mutated target peptide or (b) antigen-negative HLA-A11⁺ target cells into which a nucleotide sequence encoding the mutated target has been introduced such that the target cell expresses the mutated target as compared to the numbers of negative control T cells that secrete IFN-γ. The concentration of peptide and the negative control may be as described herein. The numbers of cells secreting IFN-γ may be measured by methods known in the art such as, for example, ELISPOT.

[0087] Preferably, the TCR of the present invention specifically binds to the abovementioned epitopes. The term "specific(ally) binding" generally indicates that a TCR binds via its antigen binding site more readily to its intended epitope than to a random, unrelated non-target antigen. Particularly the term "specifically binds" indicates that the binding specificity of the TCR will be at least about 5-fold, preferably 10-fold, more preferably 25-fold, even more preferably 50-fold,

and most preferably 100-fold or more, greater for its epitope than its binding specificity for a non-target antigen.

[0088] Each embodiment concerning the antigenic specificity for the abovementioned epitope(s) as defined herein may also be applicable to the TCR of the invention being able to recognize said mutated epitope(s) in the context of a MHC class II molecule.

[0089] The TCR of the invention is able to recognize said mutated epitope (antigenic target), e.g., mutated KRAS, in a MHC class I and/or class II-dependent manner, meaning the epitope is presented in the context of a MHC class I and/or class II molecule. "MHC class I-dependent manner," as used herein, means that the TCR elicits an immune response upon binding to a mutated target, e.g., mutated KRAS peptide as defined herein, within the context of an MHC class I molecule. The MHC class I molecule can be any MHC class I molecule known in the art. Such MHC class I molecule covers any HLA-A, HLA-B and/or HLA-C molecules. "MHC class II-dependent manner," as used herein, means that the TCR elicits an immune response upon binding to a mutated target, e.g., mutated KRAS peptide as defined herein, within the context of an MHC class II molecule.

[0090] In a preferred embodiment of the invention, the TCR as defined herein may further have antigenic specificity for the mutated epitope as defined above presented in the context of an HLA-A molecule. In a more preferred embodiment of the invention, the TCR as defined herein may further have antigenic specificity for the mutated epitope as defined above presented in the context of an HLA-A*03 molecule. In an even more preferred embodiment of the invention, the TCR as defined herein may further have antigenic specificity for the mutated epitope as defined above presented in the context of an HLA-A*11 molecule. In a most preferred embodiment of the invention, the TCR as defined herein may further have antigenic specificity for the mutated epitope as defined above presented in the context of at least any one of an HLA-A*11:01 molecule, an HLA-A*11:02 molecule, or an HLA-A*11:04 molecule. Based on the Examples it is disclosed that the novel TCR that recognizes its cognate peptide as defined above in the context of HLA-A*11:01 might also recognize the peptide presented by another HLA-A*11 subtype such as HLA-A*11:02, and/or HLA-A*11:04 and/or by other HLA alleles of the HLA-A*03 superfamily, where HLA-A*11 is one of many members from (see **Figure 5**).

[0091] The term "HLA-A*03 molecule" may also refer to an "any HLA-molecule of the HLA-A*03 super family, such as HLA-A*11".

[0092] As used herein, the term "epitope" may refer to a part of an antigen (antigenic target) that is recognized by the immune system, specifically by antibodies, B cells, or T cells. The epitope is the specific piece of the antigen to which the TCR binds to (particularly with the CDR3 as the prime determinant of antigen recognition and specificity) and is defined herein as mentioned elsewhere above.

[0093] As used herein, the term “human leukocyte antigen” or “HLA” may refer to any of various (polymorphic) proteins that are encoded by genes of the major histocompatibility complex in humans and are found on the surface of many cell types (such as white blood cells). HLA class I alleles include HLA-A, HLA-B and HLA-C alleles (<http://hla.alleles.org/genes/index.html>). The human major histocompatibility complex (MHC) is divided into 3 regions on chromosome 6p21.3: class II (centromeric), class III, and class I (telomeric), with extended class I and class II regions on either side.

[0094] As used herein, the term “major histocompatibility complex” or “MHC” may refer to a group of genes in mammals that code for cell-surface polymorphic glycoprotein molecules which display antigenic peptide fragments for T cell recognition and aid in the ability of the immune system to determine self from nonself. The MHC encodes highly polymorphic proteins, many of which are associated with the immune system. The products of classical polymorphic class I genes, human leukocyte antigen-A (HLA-A), HLA-B, and HLA-C, interact with T-cell receptor (TCR) molecules, as well as killer immunoglobulin-like receptors (KIRs) expressed on natural killer cells and some T cells.

[0095] As used herein, the term “allele” may refer to any of the alternative forms of a gene (e.g., human HLA gene) that may occur at a given locus. Each HLA allele name has a unique number corresponding to up to four sets of digits separated by colons. The length of the allele designation is dependent on the sequence of the allele and that of its nearest relative.

[0096] HLA-A alleles may be clustered into superfamilies on the basis of structural motifs and peptide binding specificity. These superfamilies reflect the broad characteristics of anchor motifs present in the peptides that they bind and present. Typically, an HLA allele name comprises the following elements: “HLA” prefix, hyphen (“-”) used to separate gene name from HLA prefix, gene name (e.g., “A”, “B”, “C”), separator “*”, field 1 depicting allele group (e.g., 03, 11, 01, 26, 24, 32, 02, 07, 15, 58, 40, 35, 08, 04, 07, 16, 03, 07 or 06 etc.), field separator “:”, field 2 depicting specific HLA protein (e.g., 01 or 02 etc.). Exemplary human class I HLA genes of the present invention include HLA-A (Class I α -chain), HLA-B (Class I α -chain) and HLA-C (Class I α -chain). Further human class I HLA alleles of the present invention include HLA-E, HLA-F, HLA-G alleles as well as pseudogenes HLA-H, HLA-J, HLA-K, HLA-L, HLA-N, HLA-P, HLA-S, HLA-T, HLA-U, HLA-V, HLA-W and HLA-Y (<http://hla.alleles.org/alleles/class1.html>). Exemplary alleles of the present invention include any human class I and class II HLA alleles, e.g., selected from the group consisting of class I HLA-A, HLA-B and HLA-C alleles. Such alleles may be selected from the following exemplary human HLA allele groups: HLA-A*03, HLA-A*11, HLA-A*01, HLA-A*26, HLA-A*24, HLA-A*32 and HLA-A*02; HLA-B*07, HLA-B*15, HLA-B*58, HLA-B*40, HLA-B*35 and HLA-B*08; HLA-C*04, HLA-C*07, HLA-C*16, HLA-C*03, HLA-C*07 and HLA-C*06 alleles. Exemplary human HLA alleles of the present invention include but are not limited to: HLA-A*03:01, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01, HLA-

A*68:01, HLA-A*11:01, HLA-A*11:02, HLA-A*11:03, HLA-A*11:04 alleles. According to <http://hla.alleles.org/alleles/index.html> there are currently 32330 HLA and related alleles described by the HLA nomenclature and included in the IPD-IMGT/HLA Database Release 3.46 (2021-10) Build 2d19adf (<https://www.ebi.ac.uk/ipd/imgt/hla/>). Any human class I HLA allele (e.g., HLA-A, HLA-B or HLA-C allele) may be within the meaning of the present invention. Any human class II HLA allele may be within the meaning of the present invention. Exemplary class II HLA alleles of the present invention further include but are not limited to alleles of HLA-DRA, HLA-DRB1, HLA-DRB2-9, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DPA1, HLA-DPB1, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB proteins (e.g., <http://hla.alleles.org/alleles/class2.html>). Further human class I and class II HLA alleles may also be queried at the IPD-IMGT/HLA Database as described above using "Allele Query Tool".

[0097] Within the context of the present invention, the HLA-A3 superfamily is of high importance within the HLA-A allotype. HLA-A*11 forms a part of the HLA-A3 superfamily which further comprises, but is not limited to, HLA-A*03:01, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01 and HLA-A*68:01, characterized by recognition of peptides with small or aliphatic residues in position 2 and basic residues at their C-terminus. All currently classified HLA-A*11 serotypes fall into the A3 superfamily (Sidney et al., 2008, BMC Immunology; 9(1)). The overwhelming majority of HLA-A*11 serotypes are the HLA-A*11:01, *11:02, *11:03, or 11:04 subtypes, the novel TCR is capable of binding to the abovementioned epitopes presented by an HLA-A*11:01, an HLA-A**11:02, and/or an HLA-A**11:04 molecule within the HLA-A*11(Habel et al., 2022, PLoS Pathog; 18(3)).

[0098] As used herein, the term "functionally expressed" may refer to HLA allele/s that is/are expressed (e.g., on cell surface) and functioning as HLA protein/s, e.g., presenting peptides derived from endogenous protein (e.g., from inside the cell). The term "functionally expressed" may in particular refer to HLA allele/s that is/are expressed (e.g., on cell surface, e.g., of the mammal of the present invention) and functioning as HLA protein/s, e.g., presenting peptides derived from endogenous protein (e.g., from inside the cell, e.g., of the mammal of the present invention) in that the corresponding MHC I polypeptides are expressed on the surface of cells, e.g., of the mammal of the present invention, and present MHC antigens to which the non-human mammal providing an antigen-specific CD8⁺ T cell response and, optionally, providing an antigen-specific CD4⁺ T cell response.

[0099] The present invention may further comprise the TCR as defined herein, wherein the TCR has said antigenic specificity for said epitope(s) as defined herein in the presence of the CD8 co-receptor. The CD8 co-receptor is known to directly bind to HLA class I molecules and to be critical for the development of CD8⁺ T cells. CD8 co-receptor stabilizes the binding of a TCR to the HLA:peptide complex and facilitates early events of the TCR signaling cascade. The present inventors showed that the TCR of the invention as defined elsewhere herein

restricted to MHC class I molecules can induce T cell activation upon antigen encounter with the need of CD8-costimulation.

[00100] Chimeric co-stimulatory receptor(s):

[00101] As used herein the term “Chimeric co-stimulatory receptor(s)”, may refer to a chimeric co-stimulatory molecule(s) or chimeric receptor(s), which may be synthetic and/or engineered cell-surface receptor(s) designed to enhance the activation and/or function of immune cell(s), particularly T-cells, preferably in the context of cancer immunotherapy. These receptors are chimeric in nature because they combine components, fragments and/or portions from different receptors (e.g., naturally occurring, recombinant and/or synthetic) to create a novel receptor with specific properties (e.g., therapeutic properties). Preferably, the structure of a chimeric co-stimulatory receptor of the present invention comprises three main components: **(1) Extracellular Domain:** this portion may be responsible for recognizing and/or binding to a specific target molecule, e.g., on cancer cell(s) and/or other cells of interest. It can be derived from various receptors (e.g., PD-1), such as antibodies and/or ligands, that are capable of binding to the target. For example, the extracellular domain (preferably comprising or consisting of SEQ ID NO: 28) might be derived from a PD-1 (Programmed Cell Death Protein 1), which is a cell surface receptor protein that plays a role in the regulation of the immune system. It is primarily found on the surface of certain immune cells, particularly T cells, B cells, and some natural killer (NK) cells. Further example, the extracellular domain might be derived from a monoclonal antibody targeting a cancer-specific antigen; Further example, the extracellular domain might be derived from CD40L; **(2) Transmembrane Domain (TMD):** this region can be derived from a natural cell surface receptor and/or can anchor the chimeric receptor in the cell membrane; Preferably, TMD of the present invention might be derived from a PD-1 and further preferably comprising or consisting of SEQ ID NO: 30; **(3) Intracellular Domain:** the intracellular domain is where the co-stimulatory signalling activity is conferred. Preferably, the intracellular domain of the present invention might be derived from 4-1BB protein and further preferably comprising or consisting of SEQ ID NO: 32. The intracellular domain of the present invention can be derived from a co-stimulatory receptor, such as CD28 and/or 4-1BB (CD137), which can provide activation signals to T cells. By incorporating a co-stimulatory signalling domain, the chimeric receptor of the present invention can be designed to provide strong activation signals to the immune cell upon binding its target. In some aspects, the present invention relates to fusion proteins comprising (a) an extracellular domain containing a polypeptide derived from PD-1 or CD40L at its N-terminus; (b) a transmembrane domain; and (c) an intracellular domain containing a polypeptide derived from 4-1BB or CD28 at its C-terminus. Also, fusion proteins with CD28 at the N-terminus and CD40L at the C-terminus are envisaged. In further aspects, the present invention relates to a fusion protein

comprising: (a) an extracellular domain (ECD) containing a polypeptide derived from PD-1 or CD40L at its N-terminus; (b) a transmembrane domain (TMD); and (c) an intracellular domain (ICD) containing a polypeptide derived from 4-1BB or CD28 at its C-terminus. Preferably, in accordance with the present invention, if the extracellular domain (ECD) contains a polypeptide derived from PD-1 at its N-terminus, the intracellular domain (ICD) contains a polypeptide derived from 4-1BB at its C-terminus and vice versa. Likewise, if the extracellular domain contains a polypeptide derived from CD40L at its N-terminus, the intracellular domain contains a polypeptide derived from CD28 at its C-terminus and vice versa. For fusion proteins with an ECD derived from CD40L and an ICD derived from CD28, it is also possible that the ICD is located N-terminally of the TMD, while the TMD is located at the very C-terminus of the fusion protein. Furthermore, the present invention relates to a fusion (i.e., chimeric) protein comprising the extracellular domain (ECD) of CD40L and the intracellular signaling domain (ICD) of CD28. In the context of the present invention the term "fusion" and "chimeric" can be used interchangeably.

[00102] In context with the present invention, unless otherwise specified herein, when a chimeric co-stimulatory receptor-expressing T cell encounters a cell expressing the target molecule (e.g., a cancer cell), the receptor's extracellular domain binds to the target, and the intracellular domain delivers co-stimulatory signals to the T cell. This activation can enhance the immune cell's ability to recognize, attack, and/or eliminate the target cells, particularly in the context of cancer immunotherapy.

[00103] PD1-41BB:

[00104] As described herein references can be made to UniProtKB Accession Numbers (<http://www.uniprot.org/>, e.g., as available in UniProt release 2023_03 published 28 Jun 2023). As described herein the term "PD1-41BB" may refer to a fusion polypeptide comprising a PD-1-derived polypeptide (e.g., wherein said PD-1 is also known as Programmed Cell Death Protein 1, e.g., having UniProt Accession Number: Q15116) and a 4-1BB-derived polypeptide (e.g., wherein said 4-1BB is also known as CD137 or TNFRS9, which can be used interchangeably, e.g., having UniProt Accession Number: Q07011). In this context, the term "derived from" may particularly mean that the polypeptide contained in the extracellular domain comprises at least a part of PD-1 protein (e.g., human PD-1), preferably the extracellular domain of PD-1, respectively. The chimeric co-stimulatory receptor comprising an extracellular domain derived from PD-1 has binding activity for PD-L1, PD-L2 or other inhibitory ligands of PD-1. As used herein, the term "derived from" PD-1 also allows that up to 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids are substituted, deleted, and/or inserted compared to a native (or parent) sequence of PD-1 (e.g. human PD-1) or part thereof (e.g., extracellular domain). In this context, the term "derived from" may particularly mean that the polypeptide contained in the

intracellular domain comprises at least a part of 4-1BB protein (e.g., human 4-1BB), preferably the intracellular domain of 4-1BB, respectively. The chimeric co-stimulatory receptor comprising an intracellular domain derived from 4-1BB is capable of increasing the proliferation rate of a T cell expressing said chimeric co-stimulatory receptor upon stimulation with PD-L1, PD-L2 or another inhibitory ligand of PD-1 and/or is capable of increasing the effector function (such as increased IFN- γ release and/or increased cytotoxicity) of a T cell expressing said chimeric co-stimulatory receptor compared to a corresponding T cell not expressing the chimeric co-stimulatory receptor. As used herein, the term "derived from" 4-1BB also allows that up to 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids are substituted, deleted, and/or inserted compared to a native (or parent) sequence of 4-1BB (human or murine, preferably human 4-1BB) or part thereof (e.g., intracellular domain).

[00105] A PD-1-4-1BB fusion polypeptide as described herein, also referred to as PD1-41BB fusion, can refer to a chimeric protein resulting from a fusion of the PD-1 and 4-1BB proteins and/or fragment(s) and/or portion(s) thereof. For example, such a fusion protein can be associated and/or used with/for cancer immunotherapy and/or is designed to harness the immune system to target cancer cells more effectively. In the context of the present invention, unless otherwise specified herein, the PD-1 portion of the fusion protein (e.g., the extracellular domain, e.g., SEQ ID NO: 28 and/or transmembrane domain, e.g., SEQ ID NO: 30) may allow the fusion polypeptide of the present invention to bind to PD-L1 and/or PD-L2 ligands on the surface of cancer cells and/or antigen-presenting cells. PD-1 binding to its ligands normally sends inhibitory signals to T cells, preventing them from attacking these cells. However, in the context of a PD-1-4-1BB fusion of the present invention, this interaction may be modified. In the context of the present invention, unless otherwise specified herein, the 4-1BB portion of the fusion protein (e.g., the intracellular domain, e.g., SEQ ID NO: 32) may provide a co-stimulatory signal to T cells when engaged. This co-stimulatory signal may help activate and/or enhance the immune response against the cancer cells, overcoming the inhibitory effects of the PD-1 portion. Accordingly, the fusion protein of the present invention may combine the checkpoint-blocking capability of PD-1 with the immune-activating potential of 4-1BB. Preferably, a PD-1-4-1BB fusion of the present invention is capable of enhancing the anti-tumor immune response, e.g., by simultaneously blocking the inhibitory signals mediated by PD-1 and providing a strong co-stimulatory signal through 4-1BB. This approach is advantageous for use in immunotherapy (e.g., for cancer treatment), as it may overcome some of the resistance mechanisms that cancer cells often use to evade the immune system.

[00106] Generally, in context with the present invention, unless otherwise specified herein, fusion proteins comprising or consisting of the extracellular domain (ECD) derived from PD-1, a transmembrane domain (TMD, e.g., derived from PD-1), and the intracellular domain (ICD) derived from 4-1BB are also referred to herein as "PD-1:4-1BB" or "PD-1:BB". Likewise,

fusion proteins comprising or consisting of the extracellular domain (ECD) derived from PD-1, a transmembrane domain (TMD), and the intracellular domain (ICD) derived from CD28 are also referred to herein as “PD-1:CD28”. In context with the present invention, unless otherwise specified herein, CD28 (e.g., having UniProt Accession Number: P10747) may refer to another cell surface receptor found on T cells, and it plays a co-stimulatory role in the activation of T cells. CD28 signalling helps promote T cell activation and proliferation when engaged by its ligands, such as B7-1 (CD80) and B7-2 (CD86), on antigen-presenting cells. Likewise, fusion proteins comprising or consisting of the extracellular domain (ECD) derived from CD40L (e.g., having UniProt Accession Number: P29965), a transmembrane domain (TMD), and the intracellular domain (ICD) derived from CD28 are also referred to herein as “CD40L:CD28”.

[00107] In context with the present invention, unless otherwise specified herein, PD-1 (e.g., having UniProt Accession Number: Q15116) is a cell surface receptor primarily found on the surface of T cells. It can play an important role in regulating the immune response by inhibiting T cell activation. For example, when PD-1 binds to its ligands PD-L1 or PD-L2, which can be found on other cells, it sends inhibitory signals to the T cell, essentially putting the brakes on the immune response. This mechanism helps prevent the immune system from attacking healthy cells and tissues, but it can also be exploited by cancer cells to evade immune surveillance.

[00108] In context with the present invention, unless otherwise specified herein, 4-1BB (also known as CD137 or TNFRS9, which can be used interchangeably, e.g., having UniProt Accession Number: Q07011) is another cell surface receptor, but it has a different role than PD-1. For example, 4-1BB is typically found on activated T cells and natural killer (NK) cells. When 4-1BB is engaged by its ligand, it provides a co-stimulatory signal that enhances the activation and proliferation of these immune cells. This can lead to a more robust immune response against pathogens or cancer cells.

[00109] In context with the present invention, the term “extracellular domain”, also known as the “extracellular region” or “extracellular portion”, may refer to a structural component of protein(s), which can be found at the outer surface of cells and/or within the extracellular matrix. This region of a protein is preferably located outside the cell membrane and/or the confines of a cellular compartment, e.g., where it may play a role in various biological functions, including cell signalling, recognition, and/or interaction with other molecules. Preferably, the extracellular domain of the present invention is a polypeptide derived from the PD-1 (e.g., human PD-1, e.g., comprising or consisting of SEQ ID NO: 28 or a variant thereof).

[00110] In context with the present invention, the term “transmembrane domain”, which can also be abbreviated as “TMD”, may refer to a structural component of integral membrane proteins. Integral membrane proteins are a class of proteins that are embedded within the lipid

bilayer of a biological membrane, such as the cell membrane (e.g., plasma membrane) and/or the membranes of organelles like the endoplasmic reticulum and/or mitochondria. Preferably, TMD of the present invention is a polypeptide derived from the PD-1 (e.g., human PD-1, e.g., comprising or consisting of SEQ ID NO: 30 or a variant thereof).

[00111] In context with the present invention, the term “intracellular domain”, which can also be referred to as “cytoplasmic domain”, may refer to a structural component of integral membrane proteins. It may refer to the portion of the protein that is located on the cytoplasmic side of a biological membrane, such as the cell membrane (e.g., plasma membrane) and/or the membranes of organelles like the endoplasmic reticulum, Golgi apparatus, and/or mitochondria. Preferably, the intracellular domain of the present invention is a polypeptide derived from 4-1BB (e.g., human 4-1BB, e.g., comprising or consisting of SEQ ID NO: 32 or a variant thereof).

[00112] The present invention may further encompass the TCR as defined herein, wherein the TCR is selected from the group consisting of a native TCR, a TCR variant, a TCR fragment, or a TCR construct.

[00113] In context with the present invention, the term “polypeptide complex”, which can be used interchangeably with “protein complex” may refer to a group of two or more individual protein or polypeptide molecules (e.g., a TCR and a chimeric co-stimulatory receptor as defined herein) that are bound together, preferably physically and functionally, to perform a specific biological function and/or task within a cell (e.g., T-cell) or organism.

[00114] In context with the present invention, the term “combination” may refer to the coexistence and/or interaction (e.g., functional interaction) of a group of two or more individual protein or polypeptide molecules (e.g., a TCR and a chimeric co-stimulatory receptor as defined herein) within a cellular context (e.g., on/in a cell, preferably a T-cell; or population of cells as define herein, e.g., population of T cells) or biological system.

[00115] In some aspects, the present invention provides/relates to a T-cell receptor (TCR) polypeptide complex and/or a combination comprising: a TCR; and a chimeric co-stimulatory receptor, wherein the TCR comprises: i) an α chain Complementarity Determining Region 3 (CDR3) comprising an amino acid sequence having at least 80 % identity to SEQ ID NO: 16; and/or ii) a β chain Complementarity Determining Region 3 (CDR3) comprising an amino acid sequence having at least 80 % identity to SEQ ID NO: 4.

[00116] **TCR variants:**

[00117] As noted previously, the term “TCR” encompasses TCR variants, which include TCR sequence variants, fragments and constructs. All TCR variants are envisaged to be functional variants of the TCR of the invention. The term “functional variant” as used herein refers to a TCR, polypeptide, or protein having substantial or significant sequence identity or

similarity to a parent TCR, its variable regions or its antigen-binding regions and shares its biological activity, i.e. its ability to specifically bind to the antigenic target for which the parent TCR of the invention has antigenic specificity to a similar, the same or even a higher extent as the TCR disclosed herein.

[00118] The term “TCR variants” includes “sequence variants” of the TCR disclosed herein, i.e. variants substantially comprising the amino acid sequence of the TCR as described above (also referred to as the “parent” TCR) but containing at least one amino acid modification (i.e. a substitution, deletion, or insertion) as compared to the “parent” / “native” TCR amino acid sequence, provided that the variant preferably retains the antigenic specificity of the inventive “parent” TCR as shown in the Examples. TCR sequence variants of the invention are typically prepared by introducing appropriate nucleotide changes into the nucleic acids encoding the “parent” TCR, or by peptide synthesis. Generally, the aforementioned amino acid modifications may be introduced into, or present in, the variable region or the constant region of the TCR, and may serve to modulate properties like binding strength and specificity, post-translational processing (e.g. glycosylation), thermodynamic stability, solubility, surface expression or TCR assembly.

[00119] As set out previously, amino acid modifications include, for example, deletions from, and/or insertions into, and/or substitutions of, residues within the amino acid sequences of the parent TCR. Exemplary insertional variants of a TCR of the invention include fusion products of said TCR and an enzyme or another functional polypeptide. Exemplary substitutional variants of a TCR of the invention are those including amino acid substitutions in variable regions or CDRs of the alpha and/or beta chain, the framework region or the constant region.

[00120] The addition of a disulfide bond in the constant region has been reported to foster correct pairing of the TCR alpha and beta chains (Kuball J et al. Blood. 2007 Mar 15; 109(6):2331-8.). Thus, the addition of one or more cysteine bonds in the constant region is also envisaged herein.

[00121] Murinization of TCRs (i.e. exchanging the human constant regions in the alpha and beta chain by their murine counterparts) is a technique that is commonly applied in order to improve cell surface expression of TCRs in host cells. Without wishing to be bound by specific theory, it is thought that murinized TCRs associate more effectively with CD3 co-receptors; and/or that preferentially pair with each other and are less prone to form mixed TCRs on human T cells engineered *ex vivo* to express the TCRs of desired antigenic specificity, but still retaining and expressing their “original” TCRs.

[00122] Recently nine amino acids responsible for the improved expression of murinized TCRs have been identified (Sommermeyer and Uckert, J Immunol. 2010 Jun 1; 184(11):6223-31) and it is envisaged to substitute one or all of the amino acid residues in the TCRs alpha

and/or beta chain constant region for their murine counterpart residues. This technique is also referred to as “minimal murinization” and offers the advantage of enhancing cell surface expression while, at the same time, reducing the number of “foreign” amino acid residues in the amino acid sequence and, thereby, the risk of immunogenicity.

[00123] In general, TCR sequence variants are envisaged to comprise at least one of the CDR1, CDR2, CDR3, alpha chain variable regions, beta chain variable regions, alpha chains and/or beta chains as disclosed herein, or comprising or consisting of an amino acid sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or identical to the amino acid sequences disclosed herein, provided that said variants exhibit comparable, the same or improved binding characteristics as compared to the TCR evaluated in the Examples.

[00124] TCR constructs and fragments:

[00125] The term “TCR” as used herein further comprises TCR constructs. The term “construct” includes proteins or polypeptides comprising at least one antigen binding domain of the TCR of the invention, but do not necessarily share the basic structure of a native TCR (i.e. variable regions incorporated into a TCR alpha chain and a TCR beta chain forming a heterodimer). TCR constructs and fragments are typically obtained by routine methods of genetic engineering and are often artificially constructed to comprise additional functional protein or polypeptide domains. In accordance with the foregoing, TCR constructs and fragments of the invention are envisaged to comprise at least one CDR3alpha and/or at least one CDR3beta as disclosed elsewhere herein. Further envisaged herein are constructs and fragments comprising at least one CDR1alpha, CDR2alpha, CDR1beta, CDR2beta, alpha chain variable region, beta chain variable region, alpha chain and/or beta chain, or combinations thereof, optionally in combination with further protein domains or moieties as exemplified herein. The TCR constructs and fragments provided herein may further be envisaged to be capable of specifically binding to the same antigenic target as the TCR described above and evaluated in the Examples.

[00126] The present invention may also comprise the TCR construct as defined herein comprising at least one TCR alpha-chain(s) and at least one TCR beta-chain(s) covalently linked to each other to form TCR heterodimers or multimers.

[00127] The term “TCR construct” encompasses heterodimers and multimers in which at least one TCR alpha chain variable region or TCR alpha-chain and at least one TCR beta-chain variable region are covalently linked to each other. In its simplest form a multivalent TCR construct according to the invention comprises a multimer of two or three or four or more TCRs associated (e. g. covalently or otherwise linked) with one another, preferably via a linker molecule.

[00128] Suitable linker molecules include, but are not limited to, multivalent attachment molecules such as avidin, streptavidin, neutravidin and extravidin, each of which has four binding sites for biotin. Thus, biotinylated TCRs can be formed into multimers having a plurality of TCR binding sites. The number of TCRs in the multimer will depend upon the quantity of TCR in relation to the quantity of linker molecule used to make the multimers, and also on the presence or absence of any other biotinylated molecules. Exemplary multimers are dimeric, trimeric, tetrameric or pentameric or higher-order multimer TCR constructs. Multimers of the invention may also comprise further functional entities such as labels or drugs or (solid) carriers.

[00129] The term “TCR construct” also encompasses TCR molecules which are linked via a suitable linker to a spheric body, preferably a uniform bead, more preferably a polystyrene bead, most preferably a bio-compatible polystyrene bead. Such TCR constructs can also be comprised of the TCR as defined herein and a bead having a pre-defined fluorescence dye incorporated into the bead.

[00130] TCR fusion proteins:

[00131] The present invention may also comprise the TCR as defined herein, further comprising one or more fusion component(s) selected from the group consisting of a Fc receptor; a Fc domain, including IgA, IgD, IgG, IgE, and IgM; a cytokine, including IL-2 or IL-15; a toxin; an antibody or an antigen-binding fragment thereof, including anti-CD3, anti-CD28, anti-CD5, anti-CD 16 or an anti- CD56 antibody or an antigen-binding fragment thereof; or a CD247 (CD3-zeta), CD28, CD137, or a CD134 domain, or combinations thereof, optionally further comprising at least one linker. These are called a “fusion protein”.

[00132] The term “TCR construct” may also relate to such fusion proteins or polypeptides comprising at least one TCR alpha chain, TCR alpha chain variable region or CDR3alpha and/or at least one TCR beta chain, TCR beta chain variable region or CDR3beta; and further one or more fusion component(s). Useful components include Fc receptors; Fc domains (derived from IgA, IgD, IgG, IgE, and IgM); cytokines (such as IL-2 or IL-15); toxins; antibodies or antigen-binding fragments thereof (such as anti-CD3, anti-CD28, anti-CD5, anti-CD 16 or anti- CD56 antibodies or antigen-binding fragments thereof); CD247 (CD3-zeta), CD28, CD137, CD134 domains; or any combinations thereof.

[00133] Exemplary antibody fragments that can be used as fusion components include fragments of full-length antibodies, such as (s)dAb, Fv, Fd, Fab, Fab', F(ab')₂ or “r IgG” (“half antibody”); modified antibody fragments such as scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, minibodies, multibodies such as triabodies or tetrabodies,

and single domain antibodies such as nanobodies or single variable domain antibodies comprising only one variable domain, which might be VHH, VH or VL.

[00134] TCR constructs of the invention may be fused to one or more antibody or antibody fragments, yielding monovalent, bivalent and polyvalent/multivalent constructs and thus monospecific constructs, specifically binding to only one target antigen as well as bispecific and polyspecific/multispecific constructs, which specifically bind more than one target antigens, e.g. two, three or more, through distinct antigen binding sites.

[00135] Optionally, a linker may be introduced between the one or more of the domains or regions of the TCR construct of the invention, i.e. between the TCR alpha chain CDR3, TCR alpha chain variable region, and/or a TCR alpha chain, the TCR beta chain CDR3, TCR beta chain variable region, and/or a TCR beta chain, and/or the one or more fusion component(s) described herein. Linkers are known in the art and have been reviewed, *inter alia*, by Chen et al. Adv Drug Deliv Rev. 2013 Oct 15; 65(10): 1357–1369. In general, linkers include flexible, cleavable and rigid linkers and will be selected depending on the type of construct and intended use/application. For example, for therapeutic application, non-immunogenic, flexible linkers are often preferred in order to ensure a certain degree of flexibility or interaction between the domains while reducing the risk of adverse immunogenic reactions. Such linkers are generally composed of small, non-polar (e.g. Gly) or polar (e.g. Ser or Thr) amino acids and include “GS” linkers consisting of stretches of Gly and Ser residues.

[00136] Particularly useful TCR constructs envisaged in accordance with the invention are those comprising at least one TCR alpha chain, TCR alpha chain variable region or CDR3 alpha as defined herein, at least one TCR beta chain, TCR beta chain variable region or CDR3 beta as defined herein, optionally linked to each other and fused, optionally via a linker, to at least one antibody or an antibody fragment (such as a single chain antibody fragment (scFv)) directed against an antigen or epitope on the surface of lymphocytes, such as a T cell. Useful antigenic targets recognized by the antibody or antibody fragment (e.g. scFv) include CD3, CD28, CD5, CD16 and CD56. Said construct can in general have any structure as long the “TCR portion” (i.e. TCR alpha and beta chain or variable regions or CDR3s thereof) retains its ability to recognize the antigenic target defined herein, and the “antibody portion” binds to the desired surface antigen or epitope, thereby recruiting and targeting the respective lymphocyte to the target cell. Such constructs may advantageously serve as “adapters” joining an antigen presenting cell displaying the antigenic target (such as a tumor cell) and a lymphocyte (such as a cytotoxic T cell or NK cell) together. Accordingly, a TCR construct of the invention may comprise at least one TCR antigen binding domain as described herein (for instance a TCR variable alpha and variable beta chain fused to each other) linked to a scFv (or other binding domain) of the desired binding specificity, e.g. CD3 or CD56. The scFv (or other binding domain) binds to T cells such as via the CD3 receptor or to CD56 for NK cell activation, and

the other to a tumor cell via the antigenic target as defined herein specifically expressed on the tumor cell. Also envisaged herein are tribodies comprising at least one TCR antigen binding domain as described herein, an scFv (or other binding domain) and a further domain e.g. for targeting the construct to a site of action within the body (e.g. an Fc domain).

[00137] Labels:

[00138] The present invention may also comprise the TCR as defined herein, further comprising at least one label.

[00139] The TCR of the invention can be labelled. Useful labels are known in the art and can be coupled to the TCR or TCR variant using routine methods, optionally via linkers of various lengths. The term "label" or "labelling group" refers to any detectable label. In general, labels fall into a variety of classes, depending on the assay in which they are to be detected - the following examples include, but are not limited to: isotopic labels, which may be radioactive or heavy isotopes, such as radioisotopes or radionuclides (e.g., ^3H , ^{14}C , ^{15}N , ^{35}S , ^{89}Zr , ^{90}Y , ^{99}Tc , ^{111}In , ^{125}I , ^{131}I); magnetic labels (e.g., magnetic particles); redox active moieties; optical dyes (including, but not limited to, chromophores, phosphors and fluorophores) such as fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors), chemiluminescent groups, and fluorophores which can be either "small molecule" fluorophores or proteinaceous fluorophores; enzymatic groups (e.g. horseradish peroxidase, β -galactosidase, luciferase, alkaline phosphatase; biotinylated groups; or predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags, etc.). Labelling is particularly envisaged when the TCR, TCR variants or especially soluble TCR constructs (such as those comprising at least one TCR alpha and/or TCR beta chain as described herein) are intended for diagnostic use.

[00140] Functional moieties:

[00141] The TCR of the invention can be modified by attaching further functional moieties, e.g. for reducing immunogenicity, increasing hydrodynamic size (size in solution) solubility and/or stability (e.g. by enhanced protection to proteolytic degradation) and/or extending serum half-life.

[00142] Exemplary functional moieties for use in accordance with the invention include peptides or protein domains binding to other proteins in the human body (such as serum albumin, the immunoglobulin Fc region or the neonatal Fc receptor (FcRn), polypeptide chains of varying length (e.g., XTEN technology or PASylation®), non-proteinaceous polymers, including, but not limited to, various polyols such as polyethylene glycol (PEGylation), polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and

polypropylene glycol, or of carbohydrates, such as hydroxyethyl starch (e.g., HESylation®) or polysialic acid (e.g., PolyXen® technology).

[00143] Other useful functional moieties include “suicide” or “safety switches” that can be used to shut off effector host cells carrying the TCR in a patient’s body. An example is the inducible Caspase 9 (iCasp9) “safety switch” described by Gargett and Brown Front Pharmacol. 2014; 5: 235. Briefly, effector host cells are modified by well-known methods to express a Caspase 9 domain whose dimerization depends on a small molecule dimerizer drug such as AP1903/CIP, and results in rapid induction of apoptosis in the modified effector cells. The system is for instance described in EP2173869 (A2). Examples for other “suicide” “safety switches” are known in the art, e.g. Herpes Simplex Virus thymidine kinase (HSV-TK), expression of CD20 and subsequent depletion using anti-CD20 antibody or myc tags (Kieback et al, Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):623-8).

[00144] Glycosylation:

[00145] TCR as defined herein with an altered glycosylation pattern may also be envisaged herein. As is known in the art, glycosylation patterns can depend on the amino acid sequence (e.g., the presence or absence of particular glycosylation amino acid residues, discussed below) and/or the host cell or organism in which the protein is produced. Glycosylation of polypeptides is typically either N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. Addition of N-linked glycosylation sites to the binding molecule is conveniently accomplished by altering the amino acid sequence such that it contains one or more tri-peptide sequences selected from asparagine-X-serine and asparagine-X-threonine (where X is any amino acid except proline). O-linked glycosylation sites may be introduced by the addition of or substitution by, one or more serine or threonine residues to the starting sequence.

[00146] Another means of glycosylation of TCRs is by chemical or enzymatic coupling of glycosides to the protein. Depending on the coupling mode used, the sugar(s) may be attached to (a) arginine and histidine, (b) free carboxyl groups, (c) free sulfhydryl groups such as those of cysteine, (d) free hydroxyl groups such as those of serine, threonine, or hydroxyproline, (e) aromatic residues such as those of phenylalanine, tyrosine, or tryptophan, or (f) the amide group of glutamine. Similarly, deglycosylation (i.e., removal of carbohydrate moieties present on the binding molecule) may be accomplished chemically, e.g. by exposing the TCR to trifluoromethanesulfonic acid, or enzymatically by employing endo- and exo-glycosidases.

[00147] Drug conjugates:

[00148] It is also conceivable to add a drug such as a small molecule compound to the TCR of the invention. Linkage can be achieved via covalent bonds, or non-covalent interactions such as through electrostatic forces. Various linkers, known in the art, can be employed in order to form the drug conjugates.

[00149] Tags:

[00150] The TCR of the invention can be modified to introduce additional domains which aid in identification, tracking, purification and/or isolation of the respective molecule (tags). Non-limiting examples of such tags comprise peptide motives known as Myc-tag, HAT-tag, HA-tag, TAP-tag, GST-tag, chitin binding domain (CBD-tag), maltose binding protein (MBP-tag), Flag-tag, Strep-tag and variants thereof (e.g. Strep II-tag), His-tag, CD20, Her2/neu tags, myc-tag, FLAG-tag, T7-tag, HA(hemagglutinin)-tag, or GFP-tags.

[00151] Epitope tags are useful examples of tags that can be incorporated into the TCR of the invention. Epitope tags are short stretches of amino acids that allow for binding of a specific antibody and therefore enable identification and tracking of the binding and movement of soluble TCRs or host cells within the patient's body or cultured (host) cells. Detection of the epitope tag, and hence, the tagged TCR, can be achieved using a number of different techniques. Examples of such techniques include: immunohistochemistry, immunoprecipitation, flow cytometry, immunofluorescence microscopy, ELISA, immunoblotting ("Western"), and affinity chromatography. The epitope tags can for instance have a length of 6 to 15 amino acids, in particular 9 to 11 amino acids. It is also possible to include more than one epitope tag in the TCR of the invention.

[00152] Tags can further be employed for stimulation and expansion of host cells carrying the TCR by cultivating the cells in the presence of binding molecules (antibodies) specific for said tag.

[00153] Soluble forms:

[00154] The TCR of the present invention can be provided in soluble form. Soluble TCRs are useful as diagnostic tools, and carriers or "adapters" that specifically target therapeutic agents or effector cells to, for instance, a cancer cell expressing the antigenic target recognized by the soluble TCR. Soluble TCRs (sTCRs) will typically be fragments or constructs comprising TCR alpha and/or beta chains, or variable regions or CDRs thereof and optionally stabilized via disulfide bonds or covalently linked via a suitable linker molecule, e.g. as described above in the context of TCR constructs of the invention. They will typically not comprise e.g. a transmembrane region. In some circumstances amino acid modifications in the polypeptide sequence may be introduced in order to enhance solubility of the molecules, and/or correct

folding and pairing of the alpha and beta chains (if desired), in particular when produced in a recombinant host that does not provide for the aforementioned features. For instance, when using *E. coli* as production host cells, folding and pairing of the TCR alpha and beta chains is typically accomplished *in vitro*. TCR according to the invention may therefore for instance comprise additional cysteine residues, as described elsewhere herein.

[00155] Besides additional cysteine bridges, other useful modifications include, for instance, the addition of leucine zippers and/or ribosomal skipping sequences, e.g. sequence 2A from picorna virus as described in Walseng et al. (2015), PLoS ONE 10(4): e0119559 to increase folding, expression and/or pairing of the TCR alpha and/or beta chains.

[00156] **Nucleic acid:**

[00157] The present invention further comprises a nucleic acid comprising a nucleotide sequence encoding the TCR as defined elsewhere herein.

[00158] The term "polynucleotide" or "nucleic acid" as used herein comprises a sequence of polyribonucleotides and polydeoxribonucleotides, e.g. modified or unmodified RNA or DNA, each in single-stranded and/or double-stranded form linear or circular, or mixtures thereof, including hybrid molecules. The nucleic acids according to this invention thus comprise DNA (such as dsDNA, ssDNA, cDNA), RNA (such as dsRNA, ssRNA, mRNA, ivtRNA), combinations thereof or derivatives (such as PNA) thereof.

[00159] A polynucleotide may comprise a conventional phosphodiester bond or a non-conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (PNA)). The polynucleotides of the invention may also contain one or more modified bases, such as, for example, tritylated bases and unusual bases such as inosine. Other modifications, including chemical, enzymatic, or metabolic modifications, are also conceivable, as long as a binding molecule of the invention can be expressed from the polynucleotide. The polynucleotide may be provided in isolated form as defined elsewhere herein. A polynucleotide may include regulatory sequences such as transcription control elements (including promoters, enhancers, operators, repressors, and transcription termination signals), ribosome binding site, introns, or the like.

[00160] The nucleic acid can comprise any nucleotide sequence which encodes the TCR of the invention. In particular, the present invention may comprise a nucleic acid comprising or consisting of a nucleotide sequence encoding the TCR of the invention of at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identity to the nucleotide sequence of SEQ ID NO: 9 and/or SEQ ID NO: 21 (see **Table 2**). Thus, the present invention may comprise a nucleic acid comprising or consisting of a nucleotide sequence encoding the TCR of the invention of at

least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identity to the nucleotide sequence of SEQ ID NO: 9. Thus, the present invention may comprise a nucleic acid comprising or consisting of a nucleotide sequence encoding the TCR of the invention of at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identity to the nucleotide sequence of SEQ ID NO: 21.

[00161] Additionally, the present invention may also comprise a nucleic acid comprising or consisting of a nucleotide sequence encoding the TCR of the invention of at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identity to the nucleotide sequence of SEQ ID NO: 13 and/or SEQ ID NO: 25 (see **Table 2**). Thus, the present invention may comprise a nucleic acid comprising or consisting of a nucleotide sequence encoding the TCR of the invention of at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identity to the nucleotide sequence of SEQ ID NO: 13. Thus, the present invention may comprise a nucleic acid comprising or consisting of a nucleotide sequence encoding the TCR of the invention of at least about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100% identity to the nucleotide sequence of SEQ ID NO: 25.

[00162] The nucleic acid described above may or may not comprise additional or altered nucleotide sequences encoding e.g., altered amino acid residues, a signal peptide to direct secretion of the encoded TCR, constant regions or other heterologous polypeptides as described herein. Such nucleic acids may thus encode fusion polypeptides, fragments, variants and other derivatives of the binding molecules described herein. The nucleotide sequences of the present invention may be codon-optimized for optimal expression in the desired host cell, e.g. a human lymphocyte; or for expression in bacterial, yeast or insect cells that are particularly envisaged for the expression of the soluble TCR of the invention. Codon-optimization refers to the exchange in a sequence of interest of codons that are generally rare in highly expressed genes of a given species by codons that are generally frequent in highly expressed genes of such species, such codons encoding the same amino acids as the codons that are being exchanged. Selection of optimum codons thus depends on codon usage of the host genome and the presence of several desirable and undesirable sequence motifs.

[00163] The term "polypeptide" is equally used herein with the term "protein". Proteins (including fragments thereof, preferably biologically active fragments, and peptides, usually having less than 30 amino acids) comprise one or more amino acids coupled to each other via a covalent peptide bond (resulting in a chain of amino acids). The term "polypeptide(s)" as used herein describes a group of molecules, which, for example, consist of more than 30 amino acids. Polypeptides may further form multimers such as dimers, trimers and higher oligomers, i.e. consisting of more than one polypeptide molecule. Polypeptide molecules forming such dimers, trimers etc. may be identical or non-identical. The corresponding higher order structures of such multimers are, consequently, termed homo- or heterodimers, homo- or heterotrimers etc. An example for a heteromultimer is an antibody molecule, which, in its naturally occurring form, consists of two identical light polypeptide chains and two identical heavy polypeptide chains. The terms "polypeptide" and "protein" also refer to naturally modified polypeptides/proteins wherein the modification is affected e.g. by post-translational modifications like glycosylation, acetylation, phosphorylation and the like. Such modifications are well known in the art.

[00164] Vector:

[00165] Further provided herein is a vector, comprising one or more of the nucleic acids as described herein. A "vector" is a nucleic acid molecule used as a vehicle to transfer (foreign) genetic material into a host cell where it can for instance be replicated and/or expressed.

[00166] The term "vector" encompasses, without limitation plasmids, viral vectors (including retroviral vectors, lentiviral vectors, adenoviral vectors, vaccinia virus vectors, polyoma virus vectors, and adenovirus-associated vectors (AAV)), phages, phagemids, cosmids and artificial chromosomes (including BACs and YACs). The vector itself is generally a nucleotide sequence, commonly a DNA sequence that comprises an insert (transgene) and a larger sequence that serves as the "backbone" of the vector. Engineered vectors typically comprise an origin for autonomous replication in the host cells (if stable expression of the polynucleotide is desired), selection markers, and restriction enzyme cleavage sites (e.g. a multiple cloning site, MCS). Vector may additionally comprise promoters, genetic markers, reporter genes, targeting sequences, and/or protein purification tags. As known to those skilled in the art, large numbers of suitable vectors are known to those of skill in the art and many are commercially available. Examples of suitable vectors are provided in J. Sambrook et al., *Molecular Cloning: A Laboratory Manual* (4th edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York (2012) and include

[00167] The vector of the present invention can be a targeting vector. Targeting vectors can be used to integrate a polynucleotide into the host cell's chromosome by methods known in the art, such as described by J. Sambrook et al., *Molecular Cloning: A Laboratory Manual*

(4th edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York (2012). Briefly, suitable means include homologous recombination or use of a hybrid recombinase that specifically targets sequences at the integration sites. Targeting vectors are typically circular and linearized before used for homologous recombination. As an alternative, the foreign polynucleotides may be DNA fragments joined by fusion PCR or synthetically constructed DNA fragments which are then recombined into the host cell. It is also possible to use heterologous recombination which results in random or non-targeted integration.

[00168] The vector of the present invention can also be an expression vector. "Expression vectors" or "expression constructs" can be used for the transcription of heterologous polynucleotide sequences, for instance those encoding the TCR of the invention, and translation of their mRNA in a suitable host cell.

[00169] Besides an origin of replication, selection markers, and restriction enzyme cleavage sites, expression vectors typically include one or more regulatory sequences operably linked to the heterologous polynucleotide to be expressed.

[00170] The term "regulatory sequence" refers to a nucleotide sequence necessary for the expression of an operably linked coding sequence of a (heterologous) polynucleotide in a particular host organism or host cell and thus include transcriptional and translational regulatory sequences. Typically, regulatory sequences required for expression of heterologous polynucleotide sequences in prokaryotes include a promoter(s), optionally operator sequence(s), and ribosome binding site(s). In eukaryotes, promoters, polyadenylation signals, enhancers and optionally splice signals are typically required. Moreover, specific initiation and secretory signals also may be introduced into the vector in order to allow for secretion of the polypeptide of interest into the culture medium.

[00171] Exemplary regulatory sequences for mammalian host cell expression include viral elements that direct high levels of protein expression in mammalian cells, such as promoters and/or enhancers derived from cytomegalovirus (CMV) (such as the CMV promoter/enhancer), Simian Virus 40 (SV40) (such as the SV40 promoter/enhancer), adenovirus, (e.g., the adenovirus major late promoter (AdMLP)) and polyoma. As set out before, the expression vectors may also include origins of replication and selectable markers.

[00172] As mentioned previously, vectors of the invention may further comprise one or more selection markers. Suitable selection markers for use with eukaryotic host cells include, without limitation, the herpes simplex virus thymidine kinase (tk), hypoxanthine-guanine phosphoribosyltransferase (hgp^{rt}), and adenine phosphoribosyltransferase (ap^{rt}) genes. Other genes include dhfr (methotrexate resistance), gpt (mycophenolic acid resistance) neo (G-418 resistance) and hyg^{ro} (hygromycin resistance). Vector amplification can be used to increase expression levels. In general, the selection marker gene can either be directly linked

to the polynucleotide sequences to be expressed or introduced into the same host cell by co-transformation.

[00173] In view of the above, the present invention thus further provides one or more of the nucleotide sequences described herein inserted into (i.e. comprised by) a vector. Specifically, the invention provides (replicable) vectors comprising a nucleotide sequence encoding the TCR of the invention, or an alpha or beta chain thereof, or an alpha or beta variable region, or any CDR alpha or CDR beta operably linked to a promoter.

[00174] The skilled person will readily be able to select a suitable expression vector based on, e.g., the host cell intended for TCR expression. Examples for suitable expression vectors are viral vectors, such as retroviral vectors e.g. MP71 vectors or retroviral SIN vectors; and lentiviral vectors or lentiviral SIN vectors. Viral vectors comprising polynucleotides encoding the TCR of the invention are for instance capable of infecting lymphocytes, which are envisaged to subsequently express the heterologous TCR. Another example for a suitable expression vector is the Sleeping Beauty (SB) transposon transposase DNA plasmid system, SB DNA plasmid. The nucleic acids and/or in particular expression vectors of the invention can also be transferred into cells by transient RNA transfection.

[00175] Currently used viral vectors for native TCR expression typically link the TCR-alpha and TCR-beta chain genes in one vector with either an internal ribosomal entry site (IRES) sequence or the 2A peptide sequence derived from a porcine teschovirus, resulting in the expression a single messenger RNA (mRNA) molecule under the control of the viral promoter within the transduced cell.

[00176] **A cell population comprising cells:**

[00177] The term "A cell population comprising cells" as used herein may refer to a group and/or collection of individual cells of the same or similar type that share certain characteristics and/or properties within a specific biological context. Cell populations of the present invention can be defined based on various criteria, such as cell type (e.g., T cells, preferably CD8⁺ T cell(s)), developmental stage, location within a tissue or organ, functional characteristics (e.g., immune cells, preferably CD8⁺ T cell(s)) and/or genetic markers (e.g., expressing a TCR and a chimeric co-stimulatory receptor as defined herein). Preferably, a cell population comprising cells of the present invention is a population of immune cells (e.g., comprising T cells, preferably CD8⁺ T cell(s)), preferably a population of T cells (e.g., comprising T cells, preferably CD8⁺ T cell(s)). In particular, the cell population of the present invention may comprise a significant percentage of cells, such as 0.1 %, 0.2 %, 0.3 %, 0.4 %, 0.5 %, 1 %, 1.5 %, 2 %, 3 %, 4 %, 4.5 % cells. A cell population of the present invention as defined herein may comprise cells which secrete at least two, (e.g. two, three, four or more) proteins. Alternatively, the cell as defined herein may secrete at least two, (e.g. two, three, four or more) proteins. Preferably,

such cell population as defined herein comprises cells which secrete at least two proteins which are selected from the group consisting of effector proteins (effector PSI), stimulatory cytokines (stimulatory PSI), chemo-attractive cytokines (chemoattractive PSI), and regulatory cytokines (regulatory PSI). Further preferably, such cell as defined herein secretes at least two proteins which are selected from the group consisting of effector proteins (effector PSI), stimulatory cytokines (stimulatory PSI), chemo-attractive cytokines (chemoattractive PSI) and regulatory cytokines (regulatory PSI).

[00178] Cell:

[00179] The term "cell" as used herein may refer to a basic structural and functional unit of life in all living organisms. Preferred cells of the present invention are immune cells, preferably T cells. A cell (e.g. T cell) or a cell population (e.g. T-cell population) as defined herein co-expressing the TCR as defined herein and the chimeric costimulatory receptor such as PD1-41BB CSR as further defined herein thus shows a higher polyfunctionality (secretion of 2 or more proteins) compared to a cell or a cell population as defined herein expressing only the TCR of the invention, but not the chimeric costimulatory receptor. T cells (or T lymphocytes) as defined herein are a type of white blood cells. There are several types of T cells including: helper T cells (CD4+ T cells), cytotoxic T cells (CD8+ T cells) and regulatory T cells (Tregs). A T cell(s) of the invention may be selected from the group consisting of: helper T cell(s) (CD4+ T cell(s)), cytotoxic T cell(s) (CD8+ T cell(s)) and regulatory T cell(s) (Tregs), preferably CD8+ T cell(s). Preferably, such cell as defined herein secretes at least two proteins, which are selected from the group consisting of effector proteins (effector PSI), stimulatory cytokines (stimulatory PSI), chemo-attractive cytokines (chemoattractive PSI) and regulatory cytokines (regulatory PSI).

[00180] Host cell:

[00181] The present invention further comprises a host cell comprising the TCR, the nucleic acid or the vector as described herein.

[00182] A variety of host cells can be used in accordance with the invention. As used herein, the term "host cell" encompasses cells which can be or has/have been recipients of polynucleotides or vectors described herein and/or express (and optionally secreting) the TCR of the present invention. The terms "cell" and "cell culture" are used interchangeably to denote the source of a TCR unless it is clearly specified otherwise. The term "host cell" also includes "host cell lines".

[00183] In general, the term "host cell" includes prokaryotic or eukaryotic cells, and also includes without limitation bacteria, yeast cells, fungi cells, plant cells, and animal cells such as insect cells and mammalian cells, e.g., murine, rat, macaque or human cells. The term "host

cell" may also encompass any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.

[00184] In view of the above, the invention thus provides, *inter alia*, host cells comprising a polynucleotide or a vector, e.g. an expression vector comprising a nucleotide sequence encoding the TCR or a TCR construct as described herein.

[00185] Polynucleotides and/or vectors of the invention can be introduced into the host cells using routine methods known in the art, e.g. by transfection, transformation, or the like.

[00186] In view of the above, the present invention thus further provides host cells comprising at least one TCR, nucleic acid and/or vector as described herein.

[00187] For expression of the TCR of the invention, a host cell may be chosen that modulates the expression of the inserted nucleotide sequences, and/or modifies and processes the gene product (i.e. RNA and/or protein) as desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of gene products may be important for the function of the TCR. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the product. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.

[00188] It may be envisaged herein to provide (a) host cells for expressing and obtaining the TCR of the invention, in particular in soluble form ("production host cells") and (b) host cells expressing the TCR of the invention and having effector function ("effector host cells").

[00189] Such "effector host cells" are particularly useful for therapeutic applications and are envisaged for administration to a subject in need thereof. Preferred "effector host cells" include lymphocytes such as cytotoxic T lymphocytes (CTLs), CD8⁺ T cells, CD4⁺ T cells, natural killer (NK) cells, natural killer T (NKT) cells, gamma/delta-T-cells. Thus, the present invention may also comprise the host cell as defined herein, which is selected from lymphocytes including but not limited to cytotoxic T lymphocytes (CTLs), CD8⁺ T cells, CD4⁺ T cells, natural killer (NK) cells, natural killer T (NKT) cells, or gamma/ delta-T-cells.

[00190] Said effector host cells can be modified using routine methods to comprise a nucleotide sequence encoding the TCR of the invention, and are envisaged to express the TCR described herein, in particular on the cell surface. For the purposes of the present invention, "modified host cells expressing the TCR of the invention" generally refers to (effector or production) host cells treated or altered to express the TCR according to the present invention, for instance by RNA transfection. Other methods of modification or transfection or transduction may also be envisaged. The term "modified host cell" thus includes "transfected", "transduced" and "genetically engineered" host cells preferably expressing the TCR of the present invention.

[00191] Preferably, such “(modified) effector host cells” (in particular “(modified) effector lymphocytes”) are capable of mediating effector functions through intracellular signal transduction upon binding of the TCR to its specific epitope. Such effector functions include for instance the release of perforin (which creates holes in the target cell membrane), granzymes (which are proteases that act intracellularly to trigger apoptosis), the expression of Fas ligand (which activates apoptosis in a Fas-bearing target cell) and the release of cytokines, preferably Th1/Tc1 cytokines such as IFN- γ , IL-2 and TNF- α . Thus, an effector host cell engineered to express the TCR of the invention that is capable recognizing and binding to its epitope in the subject to be treated is envisaged to carry out the above-mentioned effector functions, thereby killing the target (e.g. cancer) cells. Cytolysis of target cells can be assessed e.g. with the CTL fluorescent killing assay (CTL, USA) detecting the disappearance of fluorescently labeled target cells during co-culture with TCR-transfected recipient T cells.

[00192] In view of the above, effector host cells preferably express a functional TCR, i.e. that typically comprises a TCR alpha and beta chain described herein; and also the signal transducing subunits CD3 gamma, delta, epsilon and zeta (CD3 complex). Moreover, expression of co-receptors CD4 or CD8 may also be desired. Generally, lymphocytes harboring the required genes involved in antigen binding, receptor activation and downstream signalling (e.g. Lck, FYN, CD45, and/or Zap70), T cells are particularly suitable as effector host cells. However, effector host cells expressing the TCR of the invention as a “binding domain” without the CD3 signal transducing subunit and/or aforementioned downstream signalling molecules (i.e. being capable of recognizing the antigenic target described herein, but without effecting functions mediated by CD3 and/or the aforementioned downstream signalling molecules) are also envisaged herein. Such effector cells are envisaged to be capable of recognizing the epitope described herein, and optionally of effecting other functions not associated with CD3 signalling and/or signalling of the aforementioned downstream signalling molecules. Examples include NK or NKT cells expressing the TCR and being capable of e.g. releasing cytotoxic granules upon recognition of their antigenic target.

[00193] Effector host cells in particular lymphocytes such as T cells can be autologous host cells that are obtained from the subject to be treated and transformed or transduced to express the TCR of the invention. Techniques for obtaining and isolating the cells from the patient are known in the art.

[00194] “Production host cells” used for the expression of the TCR of the invention are preferably capable of expressing high amounts of recombinant protein. Exemplary mammalian host cells that can be used for as “production host cells” include Chinese Hamster Ovary (CHO cells) including DHFR minus CHO cells such as DG44 and DUXBI 1, NSO, COS (a derivative of CV1 with SV40 T antigen), HEK293 (human kidney), and SP2 (mouse myeloma) cells. Other exemplary host cell lines include, but are not limited to, HELA (human cervical carcinoma), CV1

(monkey kidney line), VERY, BHK (baby hamster kidney), MDCK, 293, WI38, R1610 (Chinese hamster fibroblast) BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), P3x63-Ag3.653 (mouse myeloma), BFA-IcIBPT (bovine endothelial cells), and RAJI (human lymphocyte). Host cell lines are typically available from commercial services, the American Tissue Culture Collection (ATCC) or from published literature.

[00195] Non-mammalian cells such as bacterial, yeast, insect or plant cells are also readily available and can also be used as “production host cells” as described above. Exemplary bacterial host cells include enterobacteriaceae, such *Escherichia coli*, *Salmonella*; Bacillaceae, such as *Bacillus subtilis*; *Pneumococcus*; *Streptococcus*, and *Haemophilus influenza*. Other host cells include yeast cells, such as *Saccharomyces cerevisiae*, and *Pichia pastoris*. Insect cells include, without limitation, *Spodoptera frugiperda* cells.

[00196] In accordance with the foregoing, conceivable expressions systems (i.e. host cells comprising an expression vector as described above) include microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus); plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid). Mammalian expression systems harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter, the cytomegalovirus (CMV) major immediate-early promoter (MIEP) promoter) are often preferred. Suitable mammalian host cells can be selected from known cell lines (e.g., COS, CHO, BLK, 293, 3T3 cells), however it is also conceivable to use lymphocytes such as cytotoxic T lymphocytes (CTLs), CD8⁺ T cells, CD4⁺ T cells, natural killer (NK) cells, natural killer T (NKT) cells, gamma/ delta-T-cells.

[00197] Method for obtaining the TCR:

[00198] In accordance with the foregoing, the present invention also comprises a method for producing or obtaining the TCR as described herein comprising the steps of (i) incubating the host cell (i.e., a production host cell) under conditions causing expression of said TCR and (ii) purifying said TCR.

[00199] The host cells harboring the expression vector are grown under conditions appropriate to the production of the TCR defined herein, in particular alpha chains and/or beta chains as described elsewhere herein, and assayed for alpha and/or beta chain protein

synthesis. For the expression of double-chained TCRs, vectors encoding both the alpha and beta chains may be co-expressed in the host cell for expression of the entire molecule.

[00200] Once a TCR of the invention has been expressed, it may be purified by any purification method known in the art, for example, by chromatography (e.g., ion exchange chromatography (e.g. hydroxylapatite chromatography), affinity chromatography, particularly Protein A, Protein G or lectin affinity chromatography, sizing column chromatography), centrifugation, differential solubility, hydrophobic interaction chromatography, or by any other standard technique for the purification of proteins. The skilled person will readily be able to select a suitable purification method based on the individual characteristics of the TCR to be recovered.

[00201] Any definitions regarding the TCR, the nucleic acid, the vector, or the host cell can be applied for the production method as defined herein, where necessary.

[00202] Pharmaceutical or diagnostic composition:

[00203] The present invention further comprises a pharmaceutical composition comprising one or more active agents, namely the TCR, the nucleic acid, the vector and/or the host cell as described herein, and, optionally, one or more pharmaceutically excipient(s). Accordingly, the use of said TCR, nucleic acid, vector and/or host cell for the manufacture of a pharmaceutical composition or medicament is also envisaged herein.

[00204] The term "pharmaceutical composition" particularly refers to a composition suitable for administering to a subject, preferably to a mammal, most preferably to a human. However, compositions suitable for administration to non-human mammal are generally also encompassed by the term.

[00205] The pharmaceutical composition and its components (i.e. active agents and optionally excipients) are preferably pharmaceutically acceptable, i.e. capable of eliciting the desired therapeutic effect without causing any undesirable local or systemic effects in the recipient. Pharmaceutically acceptable compositions of the invention may for instance be sterile. Specifically, the term "pharmaceutically acceptable" may mean approved by a regulatory agency or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

[00206] The active agent described in the foregoing (for instance the host cell or the TCR) is preferably present in the pharmaceutical composition in a therapeutically effective amount. By "therapeutically effective amount" is meant an amount of the active agent that elicits the desired therapeutic effect. Therapeutic efficacy and toxicity can be determined by standard procedures, e.g. in cell culture or in test animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be

expressed as the ratio, ED50/LD50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

[00207] The exact dosage of the TCR, nucleic acid, vector and/or host cell will be ascertainable by one skilled in the art using known techniques. Suitable dosages provide sufficient amounts of the active agent of the invention and are preferably therapeutically effective, i.e. elicit the desired therapeutic effect.

[00208] As is known in the art, adjustments for purpose of the treatment (e.g. remission maintenance vs. acute flare of disease), route, time and frequency of administration, time and frequency of administration formulation, age, body weight, general health, sex, diet, severity of the disease state, drug combination(s), reaction sensitivities, and tolerance/response to therapy may be necessary. Suitable dosage ranges, for instance for the soluble TCR as described herein, can be determined using data obtained from cell culture assays and animal studies and may include the ED50. Typically, dosage amounts may vary from 0.1 to 100000 micrograms, up to a total dose of about 2 g, depending upon the route of administration. Exemplary dosages of the active agent of the invention may be in the range from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, from about 1 mg/kg to about 10 mg/kg, from about 1 mg/kg to about 5 mg/kg, from about 0.01 mg/kg to about 1 mg/kg, or from about 0.1 mg/kg to about 1 mg/kg. Guidance as to particular dosages and methods of delivery is provided in the literature. It is recognized that treatment may require a single administration of a therapeutically effective dose or multiple administrations of a therapeutically effective dose of the active agent of the invention.

[00209] As set out previously, the pharmaceutical composition may optionally comprise one or more excipients and/or additional active agents.

[00210] The term "excipient" includes fillers, binders, disintegrants, coatings, sorbents, antiadherents, glidants, preservatives, antioxidants, flavoring, coloring, sweetening agents, solvents, co-solvents, buffering agents, chelating agents, viscosity imparting agents, surface active agents, diluents, humectants, carriers, diluents, preservatives, emulsifiers, stabilizers and tonicity modifiers. It is within the knowledge of the skilled person to select suitable excipients for preparing the desired pharmaceutical composition of the invention. Exemplary carriers for use in the pharmaceutical composition of the invention include saline, buffered saline, dextrose, and water. Typically, choice of suitable excipients will *inter alia* depend on the active agent used, the disease to be treated, and the desired formulation of the pharmaceutical composition.

[00211] The present invention further provides pharmaceutical compositions comprising one or more of the active agents specified above (for instance a host cell or the TCR of the invention), and one or more additional active agents that are suitable for treatment and/or prophylaxis of the disease to be treated. Preferred examples of additional active agents

suitable for combinations include known anti-cancer drugs such as cis-platin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodiumphotofrin II, temozolamide, topotecan, trimetreate glucuronate, auristatin E vincristine and doxorubicin; and peptide cytotoxins such as ricin, diphtheria toxin, pseudomonas bacterial exotoxin A, DNAase and RNAase; radio-nuclides such as iodine 131, rhenium 186, indium 111, yttrium 90, bismuth 210 and 213, actinium 225 and astatine 213; prodrugs, such as antibody directed enzyme pro-drugs; immuno-stimulants, such as IL-2, chemokines such as IL-8, platelet factor 4, melanoma growth stimulatory protein, etc., antibodies or fragments thereof such as anti-CD3 antibodies or fragments thereof, complement activators, xenogeneic protein domains, allogeneic protein domains, viral/bacterial protein domains and viral/bacterial peptides.

[00212] A variety of routes are applicable for administration of the pharmaceutical composition according to the present invention. Typically, administration will be accomplished parenterally. Methods of parenteral delivery include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual or intranasal administration.

[00213] The pharmaceutical composition of the invention can be formulated in various forms, depending *inter alia* on the active agent used (e.g., the TCR), e.g. in solid, liquid, gaseous or lyophilized form and may be, *inter alia*, in the form of an ointment, a cream, transdermal patches, a gel, powder, a tablet, solution, an aerosol, granules, pills, suspensions, emulsions, capsules, syrups, liquids, elixirs, extracts, tincture or fluid extracts or in a form which is particularly suitable for the desired method of administration. Processes known per se for producing medicaments are indicated in 22nd edition of Remington's Pharmaceutical Sciences (Ed. Maack Publishing Co, Easton, Pa., 2012) and may include, for instance conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. A pharmaceutical composition comprising, for instance, host cells or the TCR as described herein will typically be provided in a liquid form, and preferably comprise a pharmaceutically acceptable buffer.

[00214] After a pharmaceutical composition of the invention has been prepared it can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would for instance include amount, frequency and method of administration.

[00215] The present invention further comprises a diagnostic composition comprising one or more diagnostic agents, namely the TCR, the nucleic acid, the vector and/or the host cell as described herein, and optionally, one or more diagnostically acceptable excipient(s). Typically, said diagnostic agent will comprise means for detecting its binding to its epitope, for instance a label as described in the context of the TCR of the invention. As regards the host

cell, it is for instance conceivable to use modified host cells comprising a dye or a contrast agent that is released (instead of cytotoxic granules) upon antigen recognition.

[00216] The term “diagnostic composition” when used herein refers to a composition comprising one or more diagnostic agents of the present invention as defined herein, which can be applied for use in diagnosis *in vitro*.

[00217] Said diagnostically acceptable excipient includes also any excipient that does not itself elicit an adverse reaction, which would be harmful when used in *in vitro* and *in vivo* diagnosis. Suitable excipients are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers and lipid aggregates such as, e.g. oil droplets or liposomes. The excipient used in combination with the one or more diagnostic agents of the present invention may be water-based and forms an aqueous solution. An oil-based excipient solution containing the one or more diagnostic agents of the present invention is an alternative to the aqueous carrier solution. Either aqueous or oil-based solutions further contain thickening agents to provide the composition with the viscosity of a liniment, cream, ointment, gel, or the like. Suitable thickening agents are well known to those skilled in the art.

[00218] Diagnostically acceptable excipients according to the present invention include, by the way of illustration and not limitation, diluent, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, gliands, substances added to mask or counteract a disagreeable texture, taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. The diagnostic composition can additionally include preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, buffers, coating agents, surfactants or antioxidants.

[00219] Any definitions regarding the TCR, the nucleic acid, the vector, or the host cell can be applied for the compositions as defined herein, where necessary.

[00220] **Treatment:**

[00221] Additionally, the present invention also comprises the TCR, nucleic acid, vector, host cell and/or the pharmaceutical composition as described herein for use as a medicament and/or for use in therapy.

[00222] The TCR, nucleic acid, vector, host cell and/or pharmaceutical composition can in general be employed for treatment detection, diagnosis, prognosis, prevention and/or treatment of diseases or disorders. The term “treatment” in all its grammatical forms includes therapeutic or prophylactic treatment of a subject in need thereof. A “therapeutic or prophylactic treatment” comprises prophylactic treatments aimed at the complete prevention of clinical and/or pathological manifestations or therapeutic treatment aimed at amelioration or remission

of clinical and/or pathological manifestations. The term "treatment" thus also includes the amelioration or prevention of diseases.

[00223] The terms "subject" or "patient" are used interchangeably herein to refer to any subject, particularly a mammal, for whom therapy is desired. Mammalian subjects generally include humans, non-human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and the like. However, it will readily be understood that the TCR, nucleic acid, vector, host cell and/or pharmaceutical composition provided herein are especially envisaged for treatment of human subjects.

[00224] For therapy, the TCR of the invention, the nucleic acid, the vector (such as viral vectors), the host cell and/or the pharmaceutical composition of the invention can be administered directly to the subject in need thereof. Thus, the present invention also comprises the TCR, the nucleic acid, the vector, the host cell, and/or the pharmaceutical composition as defined herein for use in a method of detecting, diagnosing, prognosing, preventing and/or treating cancer. The invention may also comprise the TCR, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition for the use as defined herein, wherein prevention and/or treatment of cancer comprises administering at least any one of the following: the TCR, the nucleic acid, the vector, the host cell, or the pharmaceutical composition to a subject in need thereof. Said method can also comprise the steps of (a') providing one or more of the TCR, the nucleic acid, the vector, the host cell, and/or the pharmaceutical composition of the present invention; and (b') administering one or more of the abovementioned to the subject in need thereof. Optionally, the method can comprise a further step of cancer therapy, e.g. radiation, or administration of one or more anti-cancer agents.

[00225] *Ex vivo treatment:*

[00226] The present invention may also comprise the TCR, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition for the use as defined herein, wherein prevention and/or treatment of cancer comprises (a) introducing at least any one of the following: the TCR, the nucleic acid, the vector, the host cell or the pharmaceutical composition into lymphocytes comprised by a sample obtained from a subject as defined herein, thereby obtaining modified lymphocytes, and (b) administering the modified lymphocytes of step (a) to a subject in need thereof.

[00227] The treatment according to the invention may also comprise the steps of (a') providing a sample of a subject, said sample comprising lymphocytes; (b') providing one or more of the TCR, nucleic acid, vector, host cell and/or pharmaceutical composition of the invention; (c') introducing of one or more of the abovementioned of step (b') into the lymphocytes of step (a') and, thereby, obtaining modified lymphocytes; (d') administering the modified lymphocytes of step (c') to a subject in need thereof.

[00228] The lymphocytes provided in step (a') are particularly envisaged to be "effector host cells" as described in the foregoing and are advantageously selected from T cells, NK cells and/or NKT cells, especially CD8⁺ T cells; and can be obtained in a previous step (a'') from a sample –in particular a blood sample– of the subject by routine methods known in the art. It is however also conceivable to use other lymphocytes that are preferably capable of expressing the TCR of the present invention and exert the desired biological effector functions as described herein. Moreover, said lymphocytes will typically be selected for compatibility with the subject's immune system, i.e. they will preferably not elicit an immunogenic response. For instance, it is conceivable to use a "Universal Recipient Cells", i.e. universally compatible lymphocytes exerting the desired biological effector functions that can be grown and expanded *in vitro*. Use of such cells will thus obviate the need for obtaining and providing the subject's own lymphocytes in step (a').

[00229] The *ex vivo* introduction of optional step (c') can be carried out by introducing a nucleic acid or vector described herein via electroporation into the lymphocytes, or by infecting the lymphocytes with a viral vector, such as a lentiviral or retroviral vector as described previously in the context of the effector host cell. Other conceivable methods include the use of by transfection reagents, such as liposomes, or transient RNA transfection. The transfer of antigen-specific TCR genes into (primary) T cells by e.g. (retro-)viral vectors or transient RNA transfection represents a promising tool for generating tumor-associated antigen-specific T cells that can subsequently be re-introduced into the donor, where they specifically target and destroy tumor cells expressing said antigen, such as the epitope as defined herein.

[00230] Any definitions regarding the TCR, the nucleic acid, the vector, the host cell or the pharmaceutical composition can be applied for the treatments as defined herein, where necessary.

[00231] **Use:**

[00232] The present invention envisages use of the diagnostic agents described in the foregoing for detecting, diagnosing and/or prognosing cancer in a subject which can be accomplished *in vivo* or *in vitro*.

[00233] Thus, the invention provides a diagnostic composition for use in detecting, diagnosing and/or prognosing cancer in a subject *in vivo*, said composition comprising, as a diagnostic agent, the TCR, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition of the invention. The method will typically comprise (a) administering said diagnostic agent to the subject and (b) detecting binding of said diagnostic agent to its antigenic target.

[00234] Moreover, the invention provides a method of detecting, diagnosing and/or prognosing cancer in a subject *in vitro*. In detail, the present invention comprises a method of

detecting the presence of a cancer in a subject *in vitro*, comprising (a) contacting a sample obtained from a subject and comprising one or more cells with the TCR, the nucleic acid, the vector, the host cell, and/or the pharmaceutical composition, thereby forming a complex, and (b) detecting the complex, wherein detection of the complex is indicative of the presence of the cancer in the subject. In a preferred embodiment of such method the TCR as defined elsewhere herein comprises a tag as defined herein.

[00235] The present invention may also encompass a method of detecting the presence of a cancer in a subject *in vitro*, comprising the steps of (a') providing a sample of a subject, said sample comprising one or more cells; (b') contacting said sample with the TCR, the nucleic acid, the vector, the host cell, and/or the pharmaceutical composition of the invention; thereby forming a complex, and (c') detecting the complex. Said complex is envisaged to be indicative for binding of the diagnostic agent as defined herein to its antigenic target and is of the presence of a (cancer) cell expressing said antigenic target.

[00236] In both methods binding of the diagnostic agent to its antigenic target (epitope as defined herein) is detectable by using routine methods known in the art and will *inter alia* depend on the specific diagnostic agent used. Suitable labels that can be coupled to the diagnostic agent of the invention are exemplified in the section relating to labeled TCR constructs.

[00237] The present invention also comprises the use of the TCR, the nucleic acid, and/or the vector as described elsewhere herein for generating modified lymphocytes as defined herein. Means and methods for introducing, e.g. a nucleic acid and a vector into the lymphocytes have been described elsewhere herein.

[00238] Any definitions regarding the TCR, the nucleic acid, the vector, the host cell or the pharmaceutical composition can be applied for the uses, where necessary.

[00239] **Kit:**

[00240] The present invention also comprises a kit comprising the TCR, the nucleic acid, the vector, the host cell, and/or the pharmaceutical or diagnostic composition as defined herein. Thus, when a kit comprises the TCR per se, said TCR may be provided in a vial or a container. The same applies for the other components, such as the nucleic acid, the vector, the host cell, and/or the pharmaceutical or diagnostic composition.

[00241] Further it may be associated with a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration or diagnostics.

[00242] Said kit may comprise the component as described above, preferably in a vial or container, in dried form, such as a lyophilized, air-dried, or spray-dried form (in form of a

powder), for later reconstitution into a liquid form or other form prior to use. Further, said kit may also comprise the component, preferably in a vial or container, in a frozen state, being thawed prior to use.

[00243] According to the present invention, the kit comprising the component may further comprise a diagnostically or pharmaceutically acceptable excipient as defined elsewhere herein. In some embodiments, said excipient may also be comprised in one or more containers or vials in said kit, meaning said kit additionally comprising either one vial or container comprising said excipient as a mixture or said kit additionally comprising for each component such as the excipient separate vials or containers.

* * *

[00244] Although the present invention is described in detail below, it is to be understood that this invention is not limited to the particular methodologies, protocols and reagents described herein as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[00245] In the following, the elements of the present invention will be described. These elements are listed with specific embodiments, however, it should be understood that they may be combined in any manner and in any number to create additional embodiments. The variously described examples and preferred embodiments described throughout the specification should not be construed to limit the present invention to only the explicitly described embodiments. This description should be understood to support and encompass embodiments which combine the explicitly described embodiments with any number of the disclosed and/or preferred elements. Furthermore, any permutations and combinations of all elements described herein should be considered disclosed by the description of the present application unless the context indicates otherwise.

[00246] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated member, integer or step or group of members, integers or steps but not the exclusion of any other member, integer or step or group of members, integers or steps although in some embodiments such other member, integer or step or group of members, integers or steps may be excluded, i.e. the subject-matter consists in the inclusion of a stated member, integer or step or group of members, integers or steps. When used herein the term "comprising" can be substituted with the term "containing" or

"including" or sometimes when used herein with the term "having". When used herein "consisting of" excludes any element, step, or ingredient not specified.

[00247] The terms "a" and "an" and "the" and similar reference used in the context of describing the invention (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein.

[00248] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as"), provided herein is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[00249] Unless otherwise indicated, the term "at least" preceding a series of elements is to be understood to refer to every element in the series. The term "at least one" refers to one, two, three or more such as four, five, six, seven, eight, nine, ten and more. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.

[00250] The term "and/or" wherever used herein includes the meaning of "and", "or" and "all or any other combination of the elements connected by said term".

[00251] When used herein "consisting of" excludes any element, step, or ingredient not specified in the claim element. When used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.

[00252] The term "including" means "including but not limited to". "Including" and "including but not limited to" are used interchangeably.

[00253] The term "about" means plus or minus 20%, preferably plus or minus 10%, more preferably plus or minus 5%, most preferably plus or minus 1%.

[00254] Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

[00255] It should be understood that this invention is not limited to the particular methodology, protocols, material, reagents, and substances, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular

embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[00256] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, are hereby incorporated by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material.

[00257] The content of all documents and patent documents cited herein is incorporated by reference in their entirety.

[00258] The present invention further relates to the following items:

1. A T-cell receptor (TCR) polypeptide complex and/or a combination comprising:
 - a) a TCR; and
 - b) a chimeric co-stimulatory receptor, preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising one or more (e.g., two) PD-1-derived polypeptide (e.g., wherein said PD-1 is also known as Programmed Cell Death Protein 1, e.g., having UniProt Accession Number: Q15116) and 4-1BB-derived polypeptide (e.g., wherein said 4-1BB is also known as CD137 or TNFRS9, which can be used interchangeably, e.g., having UniProt Accession Number: Q07011); further preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising a CD40L-derived polypeptide and a CD28-derived polypeptide;

wherein the TCR comprises:

 - i) an α chain Complementarity Determining Region 3 (CDR3) comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 16; and/or
 - ii) a β chain Complementarity Determining Region 3 (CDR3) comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 4.
2. A cell population (preferably a T-cell population) comprising cells (e.g., isolated and/or recombinant cells, e.g., T-cells) or a cell (e.g., isolated and/or single and/or recombinant cell, e.g., T-cell) expressing:

- a) a TCR; and
- b) a chimeric co-stimulatory receptor, preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising one or more (e.g., two) PD-1-derived polypeptide (e.g., wherein said PD-1 is also known as Programmed Cell Death Protein 1, e.g., having UniProt Accession Number: Q15116) and 4-1BB-derived polypeptide (e.g., wherein said 4-1BB is also known as CD137 or TNFRS9, which can be used interchangeably, e.g., having UniProt Accession Number: Q07011); further preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising a CD40L-derived polypeptide and a CD28-derived polypeptide;

wherein the TCR comprises:

- i) an α chain Complementarity Determining Region 3 (CDR3) comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 16; and/or
 - ii) a β chain Complementarity Determining Region 3 (CDR3) comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 4.
3. The complex and/or the combination of item 1 and/or the cell population or the cell of item 2, wherein the TCR further comprises at least one (e.g., 1, 2, 3, or 4) of the following:
- i) an α chain Complementarity Determining Region 1 (CDR 1) comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 14;
 - ii) an α chain Complementarity Determining Region 2 (CDR2) comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 15;
 - iii) a β chain CDR1 comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 2; and/or

- iv) a β chain CDR2 comprising an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 3.
- 4. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR has antigenic specificity to (an) epitope(s) presented in the context of a MHC class I molecule, the epitope comprising the amino acid sequence of VVVGAVGVGK (SEQ ID NO: 1), or a fragment thereof (e.g., SEQ ID NO: 35) or a variant thereof comprising one or more (e.g. one or two) conservative amino acid substitutions (preferably corresponding to position 1, 2, 3, 4, 5, 6, 7, 8, 9 and/or 10 of SEQ ID NO: 1).
 - 5. The complex and/or the combination, and/or the cell population or the cell of item 4, wherein the TCR has antigenic specificity for said epitope(s) presented in the context of an HLA-A molecule.
 - 6. The complex and/or the combination, and/or the cell population or the cell of item 4, wherein the TCR has antigenic specificity for said epitope(s) presented in the context of an HLA-A*04 molecule.
 - 7. The complex and/or the combination, and/or the cell population or the cell of item 4, wherein the TCR has antigenic specificity for said epitope(s) presented in the context of an HLA-A*11 molecule, preferably in the context of at least any one of an HLA-A*11:01 molecule, an HLA-A*11:02 molecule, or an HLA-A*11:04 molecule.
 - 8. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the at least 80% (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity comprises conservative or highly conservative amino acid substitutions, preferably corresponding to position 1, 2, 3, 4, 5 and/or 6 of SEQ ID NO: 14; position 1, 2, 3, 4, 5 and/or 6 of SEQ ID NO: 15; position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and/or 12 of SEQ ID NO: 16; position 1, 2, 3, 4 and/or 5 of SEQ ID NO: 2; position 1, 2, 3, 4, 5 and/or 6 of SEQ ID NO: 3; and/or position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and/or 13 of SEQ ID NO: 4.

9. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR comprises at least one (e.g., 1, 2, 3, 4, 5, or 6) of the following:
- i) an α chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 14;
 - ii) an α chain CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
 - iii) an α chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16;
 - iv) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2;
 - v) a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; and/or
 - vi) a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4.
10. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR comprises:
- i) an α chain variable region comprising the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 20; and/or
 - ii) a β chain variable region comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 8.
11. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR further comprises:
- i) an α chain constant region comprising the amino acid sequence of SEQ ID NO: 22, or an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 22; and/or
 - ii) a β chain constant region comprising the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 10.
12. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR comprises:
- i) an α chain comprising the amino acid sequence of SEQ ID NO: 24, or an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%,

- 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 24; and/or
- ii) a β chain comprising the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 80 % (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 12.
13. The complex and/or the combination, and/or the cell population or the cell of any one of items 4-12, wherein the TCR has antigenic specificity for said epitope(s) in the presence of the CD8 co-receptor.
14. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR is selected from the group consisting of a native TCR, a TCR variant, a TCR fragment, and a TCR construct.
15. The complex and/or the combination, and/or the cell population or the cell of item 14, wherein the TCR construct comprises at least one TCR alpha-chain(s) and at least one TCR beta-chain(s) covalently linked to each other to form TCR heterodimers or multimers.
16. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, the TCR further comprising one or more fusion component(s) selected from the group consisting of a Fc receptor; a Fc domain, including IgA, IgD, IgG, IgE, and IgM; a cytokine, including IL-2 or IL-15; a toxin; an antibody or an antigen-binding fragment thereof, including anti-CD3, anti-CD28, anti-CD5, anti-CD 16 or an anti- CD56 antibody or an antigen-binding fragment thereof; and a CD247 (CD3-zeta), CD28, CD137, or a CD134 domain, or combinations thereof, optionally further comprising at least one linker.
17. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR further comprises at least one label.
18. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the TCR is soluble.
19. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding items, wherein the chimeric co-stimulatory receptor comprises:

- i) an extracellular domain, preferably comprising a polypeptide derived from PD-1, further preferably at its N-terminus (e.g., SEQ ID NO: 28);
 - ii) a transmembrane domain, preferably comprising a polypeptide derived from PD-1 (e.g., SEQ ID NO: 30); and/or
 - iii) an intracellular domain, preferably comprising a polypeptide derived from 4-1BB, further preferably at its C-terminus (e.g., SEQ ID NO: 32).
20. The complex and/or the combination, and/or the cell population or the cell of item 19, wherein the transmembrane domain comprises a polypeptide derived from PD-1 (e.g., SEQ ID NO: 30).
21. The complex and/or the combination, and/or the cell population or the cell of any one of items 19-20, wherein
- i) said polypeptide derived from PD-1 comprised by said extracellular and/or by said transmembrane domain is a polypeptide derived from human PD-1; and/or
 - ii) said polypeptide derived from 4-1BB comprised by said intracellular domain is a polypeptide derived from human 4-1BB.
22. The complex and/or the combination, and/or the cell population or the cell of any one of items 19-21, wherein
- i) said extracellular domain comprising a polypeptide derived from PD-1 comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions compared to SEQ ID NO: 28;
 - ii) said extracellular domain comprising a variant of the parent extracellular PD-1 polypeptide of SEQ ID NO: 28, wherein said variant comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more positions corresponding to positions of the parent polypeptide, wherein said variant having at least 80% (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%), but less than 100% sequence identity to a parent amino acid sequence of SEQ ID NO: 28;
 - iii) said transmembrane domain comprising a polypeptide derived from PD-1 comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions compared to the amino acid sequence of SEQ ID NO: 30;
 - iv) said transmembrane domain comprising a variant of the parent PD-1 transmembrane polypeptide of SEQ ID NO: 30, wherein said variant comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more

- positions corresponding to positions of the parent polypeptide, wherein said variant having at least 80% (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%), but less than 100% sequence identity to a parent amino acid sequence of SEQ ID NO: 30;
- v) said intracellular domain comprising a polypeptide derived from 4-1BB comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions compared to SEQ ID NO: 32;
- and/or
- vi) said intracellular domain comprising a variant of the parent 4-1BB intracellular polypeptide of SEQ ID NO: 32, wherein said variant comprising an alteration (e.g., a substitution, deletion and/or insertion) at one or more positions corresponding to positions of the parent polypeptide, wherein said variant having at least 80% (e.g. at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%), but less than 100% sequence identity to a parent amino acid sequence of SEQ ID NO: 32.
23. The complex and/or the combination, and/or the cell population or the cell of any one of items 19-22, wherein
- i) said extracellular domain comprises the amino acid sequence of SEQ ID NO: 28;
- ii) said transmembrane domain comprises the amino acid sequence of SEQ ID NO: 30; and/or
- iii) said intracellular domain comprises the amino acid sequence of SEQ ID NO: 32.
24. The complex and/or the combination, and/or the cell population or the cell of any one of items 19-23, wherein said fusion protein comprises the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence having at least 80% identity to SEQ ID NO: 26.
25. The cell population or the cell of any one of items 2-24, wherein the cell is selected from lymphocytes including but not limited to cytotoxic T lymphocytes (CTLs), CD8⁺ T cells, CD4⁺ T cells, natural killer (NK) cells, natural killer T (NKT) cells, and gamma/ delta-T-cells.

26. The cell population or the cell of any one of items 2-25, wherein the cell population comprises cells which secrete at least two proteins or the cell secretes at least two proteins.
27. The cell population or the cell of item 26, wherein the proteins are selected from the group consisting of effector proteins, stimulatory cytokines, chemo-attractive cytokines and regulatory cytokines.
28. The complex and/or the combination of any one of items 1, 3-24, wherein the complex comprises a cellular membrane, wherein the TCR and the chimeric co-stimulatory receptor are located in or on said membrane.
29. A nucleic acid comprising a nucleotide sequence encoding the TCR (or fragment thereof, e.g., as depicted in Table 2) as defined by any one of items 1-24 and/or a nucleotide sequence encoding the chimeric co-stimulatory receptor as defined by any one of items 1-24 (or fragment thereof, e.g., as depicted in Table 2, preferably one or more of SEQ ID NO: 27, 29, 31 and/or 33).
30. A vector comprising the nucleic acid of item 29.
31. A host cell (e.g., isolated and/or recombinant host cell) comprising the nucleic acid of item 29, or the vector of item 30.
32. A method for obtaining the TCR and the chimeric co-stimulatory receptor as defined by any one of items 1-24, comprising
 - (i) incubating the host cell of item 31 under conditions causing expression of said TCR and of said chimeric co-stimulatory receptor; and
 - (ii) purifying said TCR and said chimeric co-stimulatory receptor.
33. A pharmaceutical or diagnostic composition comprising one or more of:
 - (i) the complex and/or the combination of any one of items 1, 3-24, 28;
 - (ii) the cell population or the cell of any one of items 2-27,
 - (iii) the nucleic acid of item 29;
 - (iv) the vector of item 30; and/or
 - (v) the host cell of item 31;and, optionally, pharmaceutically excipient(s).

34. The complex and/or the combination, and/or the cell population or the cell of any one of items 1-28, the nucleic acid of item 29, the vector of item 30, the host cell of item 31 and/or the pharmaceutical composition of item 33 for use as a medicament and/or for use in therapy.
35. The complex and/or the combination, and/or the cell population or the cell of any one of items 1-28, the nucleic acid of item 29, the vector of item 30, the host cell of item 31 and/or the pharmaceutical composition of item 33 for use in a method of detecting, diagnosing, prognosing, preventing and/or treating cancer.
36. The complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition for the use of item 35, wherein prevention and/or treatment of cancer comprises:
administering at least any one of the following (i) to (vi):
- (i) the complex and/or the combination of any one of items 1, 3-24, 28;
 - (ii) the cell population or the cell of any one of items 2-27,
 - (iii) the nucleic acid of item 29;
 - (iv) the vector of item 30;
 - (v) the host cell of item 31; and/or
 - (vi) the pharmaceutical composition of item 33;
- to a subject in need thereof.
37. The complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition for the use of item 35, wherein prevention and/or treatment of cancer comprises:
- (a) introducing at least any one of the following (i) to (vi):
- (i) the complex and/or the combination of any one of items 1, 3-24, 28;
 - (ii) the cell population or the cell of any one of items 2-27,
 - (iii) the nucleic acid of item 29;
 - (iv) the vector of item 30;
 - (v) the host cell of item 31; and/or
 - (vi) the pharmaceutical composition of item 33;
- into lymphocytes comprised by a sample obtained from a subject, thereby obtaining modified lymphocytes, and
- (b) administering the modified lymphocytes of step (a) to a subject in need thereof.
38. A method of detecting the presence of a cancer in a subject *in vitro*, comprising:

- (a) contacting a sample obtained from a subject and comprising one or more cells with
 - (i) the complex and/or the combination of any one of items 1, 3-24, 28;
 - (ii) the cell population or the cell of any one of items 2-27,
 - (iii) the nucleic acid of item 29;
 - (iv) the vector of item 30;
 - (v) the host cell of item 31; and/or
 - (vi) the pharmaceutical composition of item 33;
 thereby forming a complex, and
 - (b) detecting the complex,
- wherein detection of the complex is indicative of the presence of the cancer in the subject.
39. Use of the complex and/or the combination, and/or the cell population or the cell of any one of items 1-28, the nucleic acid of item 29 and/or the vector of item 30 for generating modified lymphocytes.
40. A kit comprising the complex and/or the combination, and/or the cell population or the cell of any one of items 1-28, the nucleic acid of item 29, the vector of item 30, the host cell of item 31, and/or the pharmaceutical or diagnostic composition of item 33.
41. The complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell, the pharmaceutical and/or diagnostic composition, method, use or kit according to any one of the preceding items, carried out as shown in Examples (e.g., Figures) and/or herein below.

EXAMPLES OF THE INVENTION

[00259] In order that the invention may be readily understood and put into practical effect, some aspects of the invention are described by way of the following non-limiting examples.

[00260] Materials and Methods

[00261] Materials

[00262] Sequences

[00263] Table 2: TCR sequences and epitopes.

SEQ ID	Description	Origin	Sequence
--------	-------------	--------	----------

1	epitope_aa (mKRAS ₇₋₁₆ G12V)	synthetic derived from human	VVVGAVGVGK
2	CDR1_b_aa	synthetic derived from human	SNHLY
3	CDR2_b_aa	synthetic derived from human	FYNNEI
4	CDR3_b_aa	synthetic derived from human	CARSGTSTGELFF
5	CDR1_b_nt	artificial: codon optimized	agcaaccacctgtac
6	CDR2_b_nt	artificial: codon optimized	ttctacaacaacgagatc
7	CDR3_b_nt	artificial: codon optimized	tgcgccagaagcggcacaagc accggcgagctgtcttt
8	Vb_aa (TRBV + CDR3 + TRBJ)	synthetic derived from human	MDTWLVCWAIFSLKA GLTEPEVTQTPSHQVT QMGQEVILRCVPISNHL YFYWYRQILGQKVEFLV SFYNNEISEKSEIFDDQ FSVERPDGSNFTLKIRS TKLEDSAMYFCARSGT STGELFFGEGSRLTVL
9	Vb_nt (TRBV + CDR3 + TRBJ)	artificial: codon optimized	atggacacctggcttgctgctgg gccatcttcagcctgctgaaggc cggactgacagagcccgaagt gacacagacaccagccacca agtgaccagatgggccaaga agtgatcctgcgctgctgccc cagcaaccacctgtacttactg gtacagacagatcctgggcccag aaagtcgagttcctggtccttct acaacaacgagatcagcgaga agtccgagatcttcgacgacca gttcagcgtggaaagaccgac ggcagcaacttcaccctgaaga tcagaagcaccagctcgagg acagcgccatgtactttgcgcca gaagcggcacaagcaccggc

			gagctgttcttggagagggcag cagactgaccgtgctc
10	Cb_aa (TRBC01)	artificial: minimal murinized	EDLNKVPPEVAVFEPS KAEIAHTQKATLVCLAT GFFPDHVELSWWWNG KEVHSGVSTDPQPLKE QPALNDSRYCLSSRLR VSATFWQNPRNHFRCC VQFYGLSENDEWTQD RAKPVTQIVSAEAWGR ADCGITSASYHQQVLS ATILYEILLGKATLYAVLV SALVLMAMVKRKDF
11	Cb_nt (TRBC01)	artificial: codon optimized	gaggacctgaacaaggtgtcc ctccggaggtggcctgttcgag cccagcaaagccgagatcgcg cacaccagaaggccaccctg gtgtgcctggccaccggcttctc cccgaccacgtggagctgagct ggtgggtgaacggcaaggagg tgcacagcggcgtgagcaccg acccccagcccctgaaggagc agcccgccctgaacgacagcc gctactgcctgagcagccgcctg cgctgagcgccaccttctggca gaacccccgaaccacttccgc tgccaggtgcagttctacggcct gagcgagaacgacgagtgagc ccaggaccgcgccaagcccg gaccagatcgtgagcgccga ggcctggggccgcccactgc ggcattaccagcgcgagctacc atcagggcgtgctgagcgccac catcctgtacgagatcctgctgg gcaaggccaccctgtacgccgt gctggtgagcgccctggtgctga tggcgatggtgaagcgcaaggga cttc
12	TCRb_aa (TRBV + CDR3 + TRBJ +Cb)	artificial: C region minimal murinized	MDTWLVCWAIFSLLKA GLTEPEVTQTPSHQVT QMGQEVLRCVPISNHL YFYWYRQILGQKVEFLV SFYNNEISEKSEIFDDQ FSVERPDGSNFTLKIRS

			TKLEDSAMYFCARSGT STGELFFGEGSRLTVLE DLNKVFPPEVAVFEP AEIAHTQKATLVCLATG FFPDHVELSWVWNGK EVHSGVSTDPQPLKEQ PALNDSRYCLSSRLRVS ATFWQNPRNHFRQV QFYGLSENDEWTQDR AKPVTQIVSAEAWGRA DCGITSASYHQGVLSAT ILYEILLGKATLYAVLVSA LVLMMAMVKRKDF
13	TCRb_nt (TRBV + CDR3 + TRBJ + Cb)	artificial: codon optimized	atggacacctggctgtgtgctgg gccatcttcagcctgctgaaggc cggactgacagagcccgaagt gacacagacaccagccacca agtgaccagatgggccaaga agtgatcctgcctgcgtgccat cagcaaccacctgtacttactg gtacagacagatcctgggccag aaagtcgagttcctggttccttct acaacaacgagatcagcgaga agtccgagatcttcgacgacca gttcagcgtggaaagaccgac ggcagcaacttcaccctgaaga tcagaagcaccaagctcgagg acagcgccatgtacttttgcgcca gaagcggcacaagcacccggc gagctgttcttggagaggcag cagactgaccgtgctcaggac ctgaacaagggttccctccgga ggtggccgtgttcgagcccagc aaagccgagatcgcgacacc cagaaggccaccctggtgtgcct ggccaccggcttctccccgacc acgtggagctgagctggtgggtg

			aacggcaaggaggtgcacagc ggcgtagcaccgacccccag ccctgaaggagcagccgcc ctgaacgacagccgctactgcct gagcagccgctgcgcgtgagc gccaccttctggcagaaccccc gcaaccacttccgctgccaggtg cagttctacggcctgagcgaga acgacgagtggacccaggacc gcgccaagcccgtgaccagat cgtgagcgccgaggcctgggg ccgcgccgactgcggcattacc agcgcgagctaccatcagggc gtgctgagcgccaccatcctgta cgagatcctgtgggcaaggcc accctgtacgccgtgtgtgag cgccctggtgctgatggcgatgg tgaagcgcaaggacttc
14	CDR1_a_aa	synthetic derived from human	NSAFQY
15	CDR2_a_aa	synthetic derived from human	TYSSGN
16	CDR3_a_aa	synthetic derived from human	CAMSARNNDMRF
17	CDR1_a_nt	artificial: codon optimized	aacagcgcctccagtac
18	CDR2_a_nt	artificial: codon optimized	acatacagcagcggcaac
19	CDR3_a_nt	artificial: codon optimized	tgtgcatgagcgccggaaca acgacatgagattt
20	Va_aa (TRAV + CDR3 + TRAJ)	synthetic derived from human	MMKSLRVLLVILWLQLS WWWSQQKEVEQDPGP LSVPEGAIVSLNCTYSN SAFQYFMWYRQYSRK GPELLMYTYSSGNKED

			GRFTAQVDKSSKYISLFI RDSQPSSDSATYLCAMS ARNNDMRFGAGTRLTV KPN
21	Va_nt (TRAV + CDR3 + TRAJ)	artificial: codon optimized	atgatgaagtcctgagagtgc gctggatcatcctgtggctgcagct gtcttgggtctggtcccagcaga aagaggtggaacaggaccctg gacctgtctgttcctgagggcg ccatcgtgtccctgaactgcacct acagcaacagcgcttccagta ctcatgtggtacagacagtaca gccggaagggccccgagctgct gatgtacacatacagcagcggc aacaagaggacggccggtta cagcccaggtgacaagagca gcaagtacatcctgttcatcc gggacagccagcctagcgata gcgccacatatctgtgtccatg agcgcccggaacaacgacatg agattggcgccggaaccagac tgaccgtgaagccaat
22	Ca_aa	artificial: minimal murinized	IQNPDPVYQLRDSKSS DKSVCLFTDFDSQTNV SQSKDSDVYITDKTVLD MRSMDFKSNSAVAWSN KSDFACANAFNNSIPE DTFFPSSDVPCDVKLVE KSFETDTNLFQNLQSVI GFRILLKLVAGFNLLMTL RLWSS
23	Ca_nt	artificial: codon optimized	atccagaatccgaccccgccg tgtaccagctgcgcgacagcaa gagcagcgacaagagcgtgtg cctgttcaccgacttcgacagcc agaccaacgtgagccagagca aggacagcgacgtgtacatcac cgacaagaccgtgctggacatg cgagcatggactcaagagca acagcgccgtggcctggagca acaagagcgacttcgcctgcgc caacgcctcaacaacagcatc atccccgaggacaccttctccc cagcagcgatgtccgtgcgac gtgaagctggtggagaagagct tcgagaccgacaccaacctgaa

			cttcagaacctgagcgtgatcg gctccgcatcctgctgctaagg tgccggcttcaacctgctgatg acctgcgcctgtggagcagc
24	TCRa_aa (TRAV + CDR3 + TRAJ + Ca)	artificial: C region minimal murinized	MMKSLRVLLVILWLQLS WVWSQQKEVEQDPGP LSVPEGAIIVSLNCTYSN SAFQYFMWYRQYSRK GPELLMYTYSSGNKED GRFTAQVDKSSKYISLFI RDSQPSDSATYLCAMS ARNNDMRFGAGTRLTV KPNIQNPDPVYQLRDS KSSDKSVCLFTDFDSQ TNVSQSKDSDVYITDKT VLDMRSMDFKSNSAVA WSNKSDFACANAFNNS IIPEDTFFPSSDVPCDV KLVEKSFETDTNLFQN LSVIGFRILLKLVAGFNL LMTLRLWSS
25	TCRa_nt (TRAV + CDR3 + TRAJ + Ca)	artificial: codon optimized	atgatgaagtcctgagagtgc gctggtcatcctgtggctgcagct gtctgggtctgtcccagcaga aagaggtgaacaggaccctg gacctgtctgttctgagggcg ccatcgtgtccctgaactgcacct acagcaacagcgcctccagta cttcagtgtgtacagacagtaca gccggaagggtcccgagctgct gatgtacacatacagcagcggc aacaagaggacggccggtta cagccaggtggacaagagca gcaagtacatctccctgtcatcc gggacagccagcctagcgata gcgccacatatctgtgtccatg agcgcccggaacaacgacatg agatttggcgccggaaccagac tgaccgtgaagcccaatatcca gaatccggaccccgccgtgtac cagctgcgcgacagcaagagc agcgacaagagcgtgtgcctgtt caccgacttcgacagccagacc aacgtgagccagagcaaggac agcgacgtgtacatcaccgaca agaccgtgtgtgacatgcgcag catggacttcaagagcaacagc

			gccgtggcctggagcaacaag agcgacttcgcctgcgccaacg cctcaacaacagcatcatcccc gaggacaccttcttcccagcag cgatgtgccgtgcgacgtgaag ctggtggagaagagcttcgaga ccgacaccaacctgaactcca gaacctgagcgtgatcggttcc gcctcctgctgctgaagtggtcc ggcttcaacctgctgatgacctg cgctgtggagcagc
26	PD1-41BB_aa	artificial protein fusion	MQIPQAPWPVWVAVLQ LGWRPGWFLDSPDRP WNPPTFSPALLVVTEG DNATFTCSFSNTSESFV LNWYRMSPSNQTDKLA AFPEDRSQPGQDCRFR VTQLPNGRDFHMSVVR ARRNDSGTLYCGAISLA PKAQIKESLRAELRVTE RRAEVPTAHPSPSPRP AGQFQTLVVGTVGGGLL GSLVLLWVLAIVIKRGR KKLLYIFKQPFMRPVQT TQEEDGCSCRFPEEEE GGCEL
27	PD1-41BB_nt	artificial: codon optimized	atgcaaattcctcaagctccttg cctgtcgtgtgggcccgttctg cttgatggcggcctggtgttc ctggactctcctgacagaccctg gaatcctccaacattcagccccg ctctgctggtgttaccgagggc gataatgccacctcacctgtagc ttcagcaacaccagcgagagct tcgtgctgaactgttacagaatg agccccagcaaccagaccgac aagctggccgccttctctgagga tagatctcagccggccaggact gccggttcagagttacacagctg ccaacggccgggacttcaca tgtctgtcgtccggccagaaga aacgacagcggcacatatctgt gcggcgccatttctctgccccta

			aggctcagatcaaagagagcct gagagccgagctgagagtgc agaaagacgggccgaagtgc cacagctcaccttcacctctcc aagacctgccggccagttccag acactggtcgtgggagttgtggc ggactgctgggatctctggtgctg ctgtttgggtgctcgccgtgatca agcggggcagaaagaagctgc tgtacatctcaagcagccctcat gcggcccgtgcagaccacaca agaggaagatggctgctcctgc agattccccgaggaagaagaa ggcggctgcgaactc
28	PD1 ECD_aa	synthetic derived human	from MQIPQAPWPVVWAVLQ LGWRPGWFLDSPDRP WNPPTFSPALLVTEG DNATFTCSFSNTSEFV LNWYRMSPSNQTDKLA AFPEDRSQPGQDCRFR VTQLPNGRDFHMSVVR ARRNDSGTLYCGAISLA PKAQIKESLRAELRVTE RRAEVPTAHPSPSPRP AGQFQTLV
29	PD1 ECD_nt	artificial: codon optimized	atgcaaattcctcaagctcctgg cctgtcgtgtgggccgttctgcaa cttgatggcggcctggctggtc ctggactctcctgacagaccctg gaatcctccaacattcagccccg ctctgctggtggttaccgagggc gataatgccaccttcacctgtagc ttcagcaacaccagcgagagct tcgtgctgaactggtacagaatg agccccagcaaccagaccgac aagctggccgcctttcctgagga tagatctcagccggccaggact gccggttcagagttacacagctg cccaacggccgggacttcaca tgtctgtcgtccgggccagaaga aacgacagcggcacatatctgt gcggcgccatttcttgccccta aggctcagatcaaagagagcct

			gagagccgagctgagagtgc agaaagacgggccgaagtgcc cacagctcaccttcaccttctcc aagacctgccggccagttccag acactggc
30	PD1 TM_aa	synthetic derived from human	VGVVGGLLGSLLVLLVW VLAVI
31	PD1 TM_nt	artificial: codon optimized	gtgggagttgtggcggactgctg ggatctctggtgctgctgtttgggt gctcgccgtgac
32	41BB_ICD_aa	synthetic derived from human	KRGRKKLLYIFKQPFMR PVQTTQEEDGCSCRFP EEEEGGCEL
33	41BB_ICD_nt	artificial: codon optimized	aagcggggcagaaagaagctg ctgtacatcttcaagcagcccttc atcgggcccgctgcagaccacac aagaggaagatggctgctcctg cagattccccgaggaagaaga aggcggctgcgaactc
34	epitope_aa (mKRAS ₇₋₁₆ G12C)	synthetic derived from human	VVGACGVGK
35	epitope_aa (mKRAS ₈₋₁₆ G12V)	synthetic derived from human	VVGAVGVGK
36	epitope_aa (mKRAS ₈₋₁₆ G12C)	synthetic derived from human	VVGACGVGK
37	epitope_aa (KRAS ₁₋₂₄ WT)	synthetic derived from human	MTEYKLVVVGAGGVGK SALTIQLI

[00264] Methods**[00265] Identification and isolation of mKRAS₇₋₁₆ G12V-specific TCR from T cell repertoires of a healthy donor using *in vitro* high-throughput T cell priming technology.**

[00266] This invention describes a TCR with high specificity and sensitivity for mKRAS₇₋₁₆ G12V epitope isolated from T cell repertoires of a healthy donor using *in vitro* high-throughput T cell priming technology as follows. Particularly, the priming system employed used monocyte-derived mature dendritic cells (mDCs) isolated from peripheral blood mononuclear cells (PBMC) of HLA-A*11:01-positive healthy donor as antigen-presenting cells and autologous CD8-enriched T cells as responding cells. *In vitro* transcribed RNA (ivtRNA) encoding a fragment of the human mKRAS protein containing G12V mutation (amino acid sequence GLLKMTEYKLVVVGAVGVGKSALTIQLIQ, see SEQ ID NO: 38) served as the source of specific antigen. After electroporation into the mDCs, the mKRAS G12V-encoding ivtRNA was translated into a polypeptide, which was subsequently processed and presented as peptides by HLA-A*11:01 molecules endogenously expressed by mDCs. *In vitro* co-cultures of T cells with ivtRNA-transfected mDCs from the same donor led to de novo induction of antigen-specific T cells that served as the source of corresponding TCRs.

[00267] Subsequently, mKRAS G12V-specific T cells were identified using HLA-A*11:01 mKRAS G12V fluorescently labelled multimers and separated by single cell sorting using fluorescence-activated cell sorting (FACS) technology. After *in vitro* expansion, specific T cell clones of interest were pre-screened for differential mKRAS G12V vs. wildtype (wt) KRAS recognition on tumor target cells, and further selected using a broader tumor cell panel with multiple mKRAS G12V-endogenously positive tumor cell lines, mKRAS G12V-overexpressing tumor cell lines and wtKRAS tumor cell lines as negative controls.

[00268] Following the identification of promising T cells clones that recognized the desired mKRAS G12V epitope presented by HLA-A*11:01 molecules on solid tumor target cells but not the wtKRAS G12 epitope, the corresponding TCR sequences were analyzed by next-generation sequencing (NGS).

[00269] The resulting HLA-A*11:01-restricted mKRAS G12V-specific TCRs identified as described above were reconstructed *in silico*, cloned in a retroviral vector, transduced into recipient T cells and further tested to confirm their specificity, activity and safety in a transgenic setting.

[00270] TCR sequencing and cloning.

[00271] TCR- α and TCR- β chains of mKRAS₇₋₁₆ G12V-specific T cell clones were identified by next-generation sequencing using an established standard protocol for analysis with the MiSeq system (Illumina, San Diego, CA, USA). For sample preparation, the manufacturer's recommendations were followed using the Dynabeads mRNA DIRECT Kit

(Thermo Fisher), SMART Scribe reverse transcriptase (Takara Bio, Mountain View, CA, USA), and the MiSeq V3 Kit (Illumina). The constant regions of all TCR chains were minimally murinized to increase the stability of the TCRs (Sommermeyer et al. 2010, *J. Immunol.*; 184, 6223–6231). To allow transgenic TCR staining and enrichment using anti-human C β 1 TCR (JOVI.1) antibody, the identified TCR was reconstructed using C β 1 as constant beta chain (WO2022/038115A1). The corresponding TCR chains were linked by a P2A peptide linker (Leisegang et al. 2008, *Mol. Med.*; 86, 573-583), codon-optimized (GeneArt, Thermo Fisher) (Scholten et al. 2006, *Clin. Immunol.*; 119, 135-145), and cloned into the pES.12-6 self-inactivating gamma-retrovirus vector. The chimeric co-stimulatory receptor PD1-41BB, consisting of the extracellular and transmembrane region of PD-1 (CD279, amino acids (aa) 21–191) and the intracellular domain of 4-1BB (CD137, aa 214–255), was added to the vector 5' of the TCR and separated by a T2A element. The sequence was codon-optimized (GeneArt, Thermo Fisher) (Scholten et al. 2006, *Clin. Immunol.*; 119, 135-145), ordered from GeneArt (Thermo Fisher), and cloned into the pES.12-6 self-inactivating gamma-retrovirus vector.

[00272] Effector Cell Preparation.

[00273] Transduction, expansion and enrichment of effector cells used in the functional assays to assess specificity, activity and safety.

[00274] Fresh blood from healthy donors was collected after informed consent. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples by density gradient centrifugation using a separating solution containing the synthetic copolymer Biocoll® (BIOSELL) and Leucosep tubes (Greiner Bio-One). CD8⁺ T cells were enriched starting from PBMCs by MACS® technology. The CD8⁺ T cell Isolation kit (Miltenyi) was used to isolate untouched CD8⁺ T cells, avoiding direct labeling surface molecules on the desired cells that could interfere with subsequent applications. The MACS separation was performed according to the manufacturer's protocol. Subsequently, CD8⁺ T cells carrying endogenous C β 2-TCRs were isolated by depleting T cells carrying endogenous C β 1-TCRs by MACS® technology in combination with biotinylated anti-human C β 1 TCR antibody (JOVI.1, AnceCell).

[00275] The obtained CD8⁺ endogenous C β 2-TCR⁺ T cells were activated using Dynabeads™ Human T-Activator CD3/CD28 for T Cell Expansion and Activation (Gibco). Cell culture medium (RPMI Medium 1640; Gibco) was supplemented with 50 U/ml IL-2 (PROLEUKIN® S, Clinigen). Retroviral vector plasmids containing the TCR in combination with PD1-41BB CSR were co-transfected in HEK293FT cells with helper plasmids encoding Moloney MLV gag/pol and the GALV env gene to produce amphotropic retroviruses by using the TransIT®-LT1 transfection reagent (Mirus). Retroviral supernatants were harvested 48 h after transfection and 2 mL of filtered viral supernatant were added per well to Retronectin (Takara Bio)-coated 24-well plates that were centrifuged at 1000× g at 32 °C for 90 min. For

transduction, $0.25\text{--}0.5 \times 10^6$ activated T cells were added per 24-well. To reach higher transduction rates, the same T cells were transduced in the same manner a second time approximately 24 h after the first transduction; 18 to 24 h after transduction, T cells underwent a 10-day-phase of expansion after transfer into G-Rex flasks (Wilson Wolf, Saint Paul, MN, USA), during which they were supplied with fresh IL-2 at a final concentration of 50U/ml twice a week. The cells were harvested from the G-Rex flasks, and transduction rates were determined before the cells were enriched to obtain transgenic TCR⁺ PD1-41BB⁺ high-purity T cell populations. Enriched cells were frozen in small aliquots and 10 days prior each functional assay cells were thawed and expanded by a rapid expansion protocol by addition of a re-stimulation cocktail, as previously described (Riddell and Greenberg 1990, J. Immunol. Methods;128, 189-201).

[00276] Cell Culture.

[00277] Tumor cell lines were transduced with HLA-A*11:01-encoded molecules to allow surface expression of the desired HLA molecules. Additionally, to obtain robust and stable PDL1 expression, all selected tumor cell lines were transduced with PDL1.

[00278] K562 (ATCC, CCL-243) transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1, Dan-G (DSMZ, ACC 249) transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1, NCI-H441 (ATCC, HTB-174) transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1, DU145 (ATCC, HTB-81) transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1 and Mel624.38 (Kind gift of M. Panelli, National Institutes of Health, Bethesda, MD, USA) transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1 were all maintained in RPMI 1640 containing 10% FBS, 2mM L-glutamine, 1%NEAA and 1% Penicillin-Streptomycin at 5% CO₂. SW527 (ATCC, CRL-7940) were transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1 were maintained in DMEM containing 10% FBS, 2mM L-glutamine, 1% NEAA and 1% Penicillin-Streptomycin at 5% CO₂. SW480 (ATCC, CCL-228) transduced with either HLA-A*11 only or HLA-A*11 in combination with PDL1 were maintained in Leibovitz L-15 Medium containing 10% FBS and 1% Penicillin-Streptomycin at 0% CO₂.

[00279] Primary HLA-A*11:01-positive normal human renal cortical epithelial cells (HRCEpC, PromoCell, Heidelberg, Germany), primary HLA-A*11:01-positive normal human cardiac fibroblasts (HCF-c, PromoCell), primary HLA-A*11:01-positive normal human atrial cardiac fibroblasts (NHCF-A, Lonza, Basel, Switzerland), primary HLA-A*11:01-positive normal human lung fibroblasts (NHLF, Lonza), induced pluripotent stem cell-derived HLA-A*11:01-transfected iCell Cardiomyocytes (iCardio, Fujifilm Cellular Dynamics, Madison, WI, USA), induced pluripotent stem cell-derived HLA-A*11:01-transduced endothelial cells (iEC, Fujifilm Cellular Dynamics), induced pluripotent stem cell-derived HLA-A*11:01-transfected

astrocytes (iAstro, Fujifilm Cellular Dynamics) were cultured according to manufacturers' instructions.

[00280] Cell Surface Staining for Flow Cytometry and FACS.

[00281] Cell surface marker staining was done according to standard protocols established previously (Wilde et al. 2009, Blood; 114, 2131-2139; Wilde et al. 2012, Oncoimmunology; 1, 129-140). The following fluorochrome-labeled antibodies were used according to manufacturers' instructions: anti-human CD8-PB/APC (clone RPA-T8, BD, Biosciences), anti-human CD4-APC (clone RPA-T4, BD, Biosciences), PD-1-APC (clone MIH4, Invitrogen), anti-human C β 1 TCR-PE (JOVI.1, BD). Flow cytometric analysis was performed on a MACSQuant X (Miltenyi Biotec) or a BD LSRFortessa Flow Cytometer (BD). For data analyses, FlowJo 10.2 software (FlowJo, Ashland, OR, USA) was used. Multimer staining was performed by using fluorochrome-labeled custom-synthesized tetramers (mKRAS₇₋₁₆ G12V peptide/HLA-A*11:01 and mKRAS₈₋₁₆ G12V peptide/HLA-A*11:01, ImmunAware) according to manufacturer's instructions. Cell sorting was conducted using either FACSaria Fusion flow cytometer (BD) or an SH800S cell sorter (Sony).

[00282] IFN- γ Release Assay.

[00283] IFN- γ release by T cells in response to different target cells was assessed in co-culture supernatants after 20 h of stimulation by enzyme-linked immunosorbent assay (ELISA). To assess specificity, activity and safety, co-culture experiments were performed using different panels of target cells comprising tumor cell lines, mKRAS₇₋₁₆ G12V peptide-loaded targets, mKRAS₈₋₁₆ G12V peptide-loaded targets, KRAS₈₋₁₆ wild type peptide-loaded targets, LCL library, K562 library, mismatched peptide-loaded targets, *in vitro* transcribed RNA (*ivtRNA*)-transfected target cells and a panel of healthy cells. Peptides were ordered at Peptides&Elephants GmbH. mMMESSAGE mMACHINE™ T7 kit (Thermo Fischer Scientific) was used to produce *ivtRNA* according to manufacturer's instructions.

[00284] For peptide loading, target cells were harvested, counted and adjusted to 1×10^6 cells/ml using appropriate medium in a tube. Subsequently, the required amount of peptide was added to the cells to reach the desired concentration. Cells were incubated for 1h and 30 minutes at 37°C. After incubation, the appropriate medium was added to a final volume of 15 ml. Cells were centrifuged (350 x g for five minutes) and the supernatant was discarded to remove unbound peptides. Cells were resuspended in fresh medium at the required concentration for the subsequent applications.

[00285] For *ivtRNA* transfection, K562 target cells were harvested, counted and washed once with RPMI1640 medium without serum. Cells were adjusted at $2 - 3 \times 10^6$ cells/200 μ l in medium without serum and 200 μ l of the cell suspension were transferred into a pre-cooled

electroporation cuvette. Subsequently, either 20 µg of *miRNA* or 20 µl of water (negative control) were added into the cuvette. The suspension was shortly mixed by pipetting and then quickly electroporated using the Gene Pulser Xcell™ device (BioRad, Hercules, CA, USA). Electroporation was performed using an exponential protocol at 300 V and 300 µF. Immediately after electroporation, cells were transferred into the appropriate fresh medium and placed into the incubator. After three hours, cells were counted and resuspended at the adequate concentrations for further applications.

[00286] Co-cultures were performed at effector to target ratios between 2:1 and 1:2 ($1-2 \times 10^4$ cells effectors/96-well). Cytokine concentrations were determined using ELISA kits (Thermo Fisher; BD). The OD measurement was performed using a Multiskan Microplate-Photometer (Thermo Fisher). Background-corrected OD values were used for extrapolation using a third-degree polynomial.

[00287] Cytotoxicity Assay.

[00288] Tumor cell lysis was assessed using either IncuCyte S3® or Zoom® device (Sartorius, Goettingen, Germany) and following manufacturer's recommendations for real-time quantitative live-cell imaging. Hence, tumor cells were transduced with NucLightRed (Sartorius) and seeded into 96-well flat-bottom plates 24 h prior to the addition of TCR⁺PD1-41BB-transduced T cells at E:T ratio of 2:1 (2×10^4 effectors / 96-well). As positive controls, in some functional assays mKRAS₇₋₁₆ G12V peptide was added at the desired concentration into the wells containing pre-seeded tumor cell lines and incubated for 1h 30 minutes at 37°C. Lysis of tumor cells was monitored by imaging the plates at regular intervals (every 4 h). The number of NucLightRed-labeled tumor cells over time was calculated using IncuCyte software (Sartorius).

[00289] To determine the cytotoxicity mediated by transduced CD8⁺ T cells in a 3-dimensional (3D) setting, NucLightRed-labeled tumor cells were seeded in 96-well ultra-low attachment plates (ULA; Corning, New York, NY, USA) to form 3D spheroid structures. Three to five days after seeding the tumor cells, 2×10^4 T cells were added to the ULA plates containing the tumor spheroids. Tumor cell lysis was monitored by imaging the plates every 4 h using either IncuCyte S3® or Zoom® device (Sartorius). For repeated challenge of the transduced T cells with tumor cells, pre-seeded NucLight-Red-labeled tumor cell spheroids were transferred from ULA plates to the co-culture plates at different time points. Lysis of tumor cell spheroids was determined using the spheroid setting in IncuCyte software (Sartorius).

[00290] Protein secretion.

[00291] TCR-transduced CD8⁺ T cells with (TCR+PD1-41BB) and without (TCR) co-expression of PD1-41BB CSR were analyzed after 24 hours of co-culture with mKRAS G12V-

positive DAN-G_A11_PD-L1 tumor cells using single-cell proteomic analysis of a panel of 32 secreted cytokines, chemokines, and cytotoxic molecules (IsoLight® technology, PhenomeX). Cells secreting 2 or more cytokines were considered polyfunctional. Polyfunctional Strength Index (PSI) of the displayed samples was defined as the number of T cells secreting more than 2 effector molecules per cell (polyfunctional T cells) multiplied by mean fluorescence intensity (MFI) of the proteins secreted by the respective cells and categorized in proteins associated with effector, stimulatory, chemo-attractive, regulatory and inflammatory properties.

[00292] Results

[00293] Example 1: High and robust transgenic TCR and PD1-41BB CSR expression.

[00294] The identified TCR was expressed in combination with PD1-41BB co-stimulatory switch receptor (CSR) in a transgenic setting to assess specificity, activity and safety. TCR was reconstructed using human minimally murinized constant regions (of note, constant beta 1 region (C β 1) was used for TCR reconstruction) linked to PD1-41BB CSR and cloned into a retroviral vector. CD8-enriched/C β 1-depleted T cells derived from healthy donors were activated using anti-CD3/CD28 beads in the presence of IL-2 and transduced with retroviral particles containing the sequence of the TCR linked to PD1-41BB CSR. Untransduced CD8⁺ T cells were prepared in the same manner and used as controls. After transduction and expansion, CD8⁺ T cells were enriched using anti-TCR C β 1 antibody and anti-PD1 antibody by fluorescence-activated cell sorting (FACS). After enrichment and rapid expansion protocol, CD8⁺ T cells were stained with anti-TCR C β 1, anti-PD1 and anti-CD8 antibodies and analyzed by flow cytometry to assess transduction efficiency and expression levels of the transgenes.

[00295] Binding of TCR C β 1 antibody and PD1 antibody to TCR + PD1-41BB-transduced CD8⁺ T cells indicated efficient transduction with high expression levels of the transgenic TCR which correlated with the expression of the transgenic PD1-41BB CSR (**Figure 1**). PD1 expression was not detected on untransduced CD8⁺ T cells. These results demonstrated that co-expression of the PD1-41BB CSR and the transgenic TCR was possible in CD8⁺ T cells and resulted in similar expression of both constructs on the cell surface.

[00296] Example 2: High mKRAS₇₋₁₆ G12V (10-mer) multimer binding.

[00297] Multimer binding is first proof of transgenic TCR functionality. Therefore, after an enrichment and rapid expansion protocol, TCR + PD1-41BB-transduced CD8⁺ T cells were stained with mKRAS₇₋₁₆ G12V (10-mer) HLA-A*11:01 multimer and analyzed by flow cytometry. Results showed high and robust 10-mer multimer binding for TCR + PD1-41BB-transduced T

cells (**Figure 2**). These findings indicated binding of TCR + PD1-41BB CSR to HLA-A*11:01 multimer loaded with mKRAS₇₋₁₆ G12V 10-mer peptide. Importantly, 10-mer length peptide variant has been described as the most abundant and stable mKRAS G12V peptide presented on HLA-A*11:01 molecules in tumor cells by mass spectrometry analysis (Jaewon Choi et al. 2021, Cell Rep Methods; Adham S. Bear et al. 2021, Nature Communications).

[00298] Example 3: Exclusive mKRAS₇₋₁₆ G12V specificity with no KRAS wild-type recognition.

[00299] To demonstrate exclusive mKRAS₇₋₁₆ G12V peptide specificity, TCR + PD1-41BB-transduced CD8⁺ T cells were co-cultured with PDL1-transduced K562 cells expressing transgenic HLA-A*11:01-encoding molecules (hereafter designated as K562_A11_PDL1) loaded with either mKRAS₇₋₁₆ G12V peptide or KRAS₇₋₁₆ wild-type peptide at high concentration (10⁻⁵M). Additionally, CD8⁺ T cell samples were also co-cultured with K562_A11_PDL1 cells transfected with either ivtRNA encoding a fragment of mKRAS G12V gene (~402 bp) or ivtRNA encoding a fragment of KRAS G12 wild-type gene (~402 bp). ivtRNA-transfected targets served to assess the capacity of TCR+ PD1-41BB CSR-transduced CD8⁺ T cells to recognize KRAS epitopes when processed and presented by internal cellular pathways. Unloaded and untransfected K562_A11_PDL1 cells were included as negative target controls. Untransduced CD8⁺ T cells served as internal effector controls. After 20 hours (h) of co-culture, an ELISA was performed to evaluate IFN-γ secretion by T cells.

[00300] TCR + PD1-41BB-transduced CD8⁺ T cells recognized only K562_A11_PDL1 cells when loaded with either mKRAS₇₋₁₆ G12V peptide or transfected with mKRAS G12V ivtRNA. No IFN-γ release was observed in response to target cells expressing KRAS₇₋₁₆ wild-type (**Figure 3**). These results showed exclusive mKRAS₇₋₁₆ G12V peptide specificity of TCR + PD1-41BB CSR-transduced CD8⁺ T cells (no recognition of KRAS wild-type) and the capacity to recognize the epitope when processed and presented by cellular internal pathways.

[00301] Example 4: High peptide sensitivity for mKRAS₇₋₁₆ G12V (10-mer) epitope.

[00302] Functional avidity refers to the accumulated strength of multiple affinities of individual non-covalent binding interactions, such as the transgenic TCR and the peptide-HLA complex. As such the functional avidity of TCR-transduced T cells serves as a measure of peptide sensitivity. TCRs conferring high peptide sensitivity can recognize lower amounts of peptide. To investigate peptide sensitivity of TCR + PD1-41BB-transgenic CD8⁺ T cells, a co-culture experiment was performed using K562_A11_PDL1 cells loaded with graded amounts of mKRAS₇₋₁₆ G12V (10-mer) peptide (10⁻⁵ M to 10⁻¹² M). Target cells were also loaded with KRAS₇₋₁₆ wild-type (10-mer) peptide at maximum concentration as internal controls. Additionally, graded amounts of mKRAS₈₋₁₆ G12V (9-mer) peptide (10⁻⁵ M to 10⁻¹² M) were

tested for direct comparison of peptide sensitivity for the two peptide length variants. After 20 h of co-culture, an ELISA was performed to evaluate IFN- γ secretion by T cells. Maximal IFN- γ release per effector cell sample was set to 100%. Based on this, the relative IFN- γ release was calculated and used in a non-linear regression analysis. TCR + PD1-41BB-transgenic CD8⁺ T showed high peptide sensitivity for mKRAS₇₋₁₆ G12V (10-mer) peptide, whereas peptide sensitivity was much lower in response to mKRAS₈₋₁₆ G12V (9-mer) peptide (**Figure 4**). These findings confirmed the preferred binding of TCR + PD1-41BB-transduced CD8⁺ T cells to mKRAS₇₋₁₆ G12V (10-mer) peptide requiring only very low amounts of 10-mer peptide for activation.

[00303] Example 5: Peptide-specific restriction to three different HLA-A*11 subtypes.

[00304] Overall, four HLA*11 subtypes have been described (HLA-A*11:01, HLA-A*11:02, HLA-A*11:03, HLA-A*11:04) which show only very slight differences in their amino acid sequences. Additionally, HLA class I molecules can be clustered into groups (designated as HLA supertype families) representing sets of molecules that share largely overlapping peptide binding specificity. HLA-A*11:01 has been described as a member of the HLA-A*03 supertype family together with HLA-A*03:01, HLA-A*30:01, HLA-A*31:01, HLA-A*33:01 and HLA-A*68:01. Hence, a specific TCR that recognizes its cognate peptide in the context of HLA-A*11:01 might also recognize the peptide presented by another HLA-A*11 subtype and/or by other HLA alleles of the HLA-A*03 superfamily.

[00305] To determine the target peptide-specific HLA restriction fine-typing and potentially broaden the patient cohort, TCR was characterized in the context of the HLA-A*11 subtypes and HLA-A*03 supertype family members. CD8⁺ T cells expressing either no transgenic TCR or the combination of TCR and PD1-41BB CSR were co-cultured with HLA-transduced K562 cell samples. Each K562 sample expressed individual transgenic HLA molecules previously described and was tested after mKRAS₇₋₁₆ G12V peptide loading (10⁻⁵M). IFN- γ release was evaluated by ELISA 20 h after setting up the co-culture.

[00306] TCR + PD1-41BB-transduced CD8⁺ T cells recognized mKRAS₇₋₁₆ G12V peptide presented by HLA molecules encoded by HLA-A*11:02 and HLA-A*11:04 at similar levels compared to HLA-A*11:01 (**Figure 5**). In conclusion, these results demonstrated that TCR + PD1-41BB presented peptide-specific restriction to three different HLA-A*11 subtypes.

[00307] Example 6: No signs of target peptide-independent cross-recognition of global frequent HLA allotypes.

[00308] To investigate potential target peptide-independent cross-recognition of frequent HLA allotypes, two cellular libraries were used as target cells in a co-culture

experiment. The first library comprised 70 lymphoblastoid cell lines (LCLs, LCL library) covering the most frequent HLA-A, -B and -C alleles in Asian and USA/European Caucasian populations. HLA-A, -B and -C alleles exhibiting HLA frequencies of more than 0.5% were covered by at least one LCL sample and HLA-A, -B and -C alleles exhibiting HLA frequencies over 5% were covered by at least two LCL samples. The second library comprised 31 K562 cell samples transduced with individual HLA molecules (K562 library) covering HLA-A alleles exhibiting HLA frequencies over 2.5% in Asian populations and HLA-B and HLA-C alleles most frequent in Asian populations not or not fully covered in LCL library.

[00309] TCR + PD1-41BB-transduced CD8⁺ T cells and untransduced CD8⁺ T cells were co-cultured with the two libraries. K562_A11 cells loaded with mKRAS₇₋₁₆ G12V peptide (10⁻⁵M) served as an internal positive target control. IFN-γ secretion was evaluated by ELISA 20 h after setting up the co-culture.

[00310] No recognition of any LCL and K562 cell sample was observed by CD8⁺ T cells transduced with TCR + PD1-41BB (**Figure 6A and 6B**). Only the positive target control led to activation of TCR + PD1-41BB-transgenic CD8⁺ T cells. Altogether, these data showed no signs of target peptide-independent cross-recognition of frequent HLA allotypes mediated by TCR + PD1-41BB.

[00311] **Example 7: Successful de-risking of potential peptide off-target toxicity.**

[00312] Off-target toxicities can arise when TCRs recognize not only the specific target peptide, but also other peptides that share a high sequence homology with the original peptide. To identify peptide candidates that show a high sequence similarity with the specific target peptide and are likely to be found in the processed HLA-A*11:01-presented human peptidome, computational tools have to be employed to generate a list of potentially cross-recognized peptides that can subsequently be synthesized and tested for recognition by TCR-transduced T cells in co-culture experiments.

[00313] By using the computational tool Expitope 2.0® (Jaravine V, Mösch A, Raffegerst S, et al. 2017; BMC Cancer;17(1):892), 299 candidate mismatched peptides could be identified containing up to 4 amino acid differences compared to the target mKRAS₇₋₁₆ G12V peptide.

[00314] A co-culture experiment was performed using K562_A11_PDL1 cells loaded with the selected 299 mismatched peptides individually (10⁻⁶ M). Target cells loaded with mKRAS₇₋₁₆ G12V peptide (10⁻⁵ M, 10⁻⁶ M, 10⁻⁷ M) served as positive controls while unloaded targets served as negative controls. TCR + PD1-41BB-transduced CD8⁺ T cells as well as untransduced CD8⁺ T cells were utilized as effector cells. IFN-γ secretion was assessed by ELISA 20 h after co-culture.

[00315] The majority of the tested peptides did not lead to activation of TCR + PD1-41BB-transduced CD8⁺ T cells, showing they were not likely to cause off-target toxicities.

However, 3 out of 299 tested mismatched peptides were recognized by TCR + PD141BB-transduced CD8⁺ T cells to some degree at the tested concentrations and therefore were further tested. Since exogenous loading of peptides at high concentration does not necessarily translate into physiological recognition of endogenously processed and presented peptides, the identified recognized peptides were tested for their potential to induce IFN- γ release mediated by TCR + PD1-41BB-transgenic CD8⁺ T cells when the peptides were translated from ivtRNA and endogenously processed and presented by K562_A11_PDL1 cells. Midi-gene fragments were designed to cover between 90 and 200-base pairs (bp) of the original gene sequence 5' and 3' of the respective peptide-coding region and linked to a GFP reporter gene. Cross-recognized peptides can be de-risked if they are not processed from the original protein, fail to be loaded on HLA molecules endogenously after overexpression in target cells or are not able to trigger activation of TCR + PD1-41BB-transgenic CD8⁺ T cells.

[00316] Co-culture experiments were established by using TCR + PD1-41BB-transduced CD8⁺ T cells and mismatched peptide midi-gene fragment ivtRNA-transfected K562_A11_PDL1 target cells. Target cells transfected with mKRAS₇₋₁₆ G12V midi-gene fragment ivtRNA (fragment spanning mKRAS₇₋₁₆ G12V peptide-coding region and linked to GFP) were included as positive target control. Water electroporation of target cells served as negative target control. The transfection efficiency of target cells was evaluated by flow cytometry analyzing GFP signals. IFN- γ secretion was evaluated by ELISA 20 h after setting up the co-culture.

[00317] All ivtRNA-transfected K562_A11_PDL1 cells showed GFP expression, confirming successful and efficient transfection (**Figure 7A**). As expected, K562_A11_PDL1 cells transfected with the ivtRNA construct encoding mKRAS₇₋₁₆ G12V peptide were recognized by TCR + PD1-41BB-transgenic CD8⁺ T cells. By contrast, none of the intracellular processed mismatched peptides were recognized (**Figure 7B**). Therefore, all mismatched peptides were successfully de-risked indicating that they are not likely to cause off-target toxicities.

[00318] **Example 8: No signs of off-target toxicity were identified using a panel of healthy cell samples.**

[00319] The aim of this experiment was to assess potential off-target toxicities that could be caused by TCR + PD1-41BB-transduced CD8⁺ T cells. HLA-A*11:01-positive primary healthy cells and induced pluripotent stem cell (iPS)-derived cell lines representing essential organs were tested for recognition by TCR + PD1-41BB-transduced CD8⁺ T cells. These healthy cell samples had either endogenous or transgenic expression of HLA-A*11:01-encoded molecules on their cell surface. In line with the properties of the individual targets, healthy cells were seeded one to seven days prior to start of the co-culture at different cell densities as per manufacturer's instructions and cultured in monolayers in flat bottom wells.

Target cells loaded with mKRAS₇₋₁₆ G12V peptide (10⁻⁵M) were included as internal positive target controls. IFN-γ secretion was evaluated by ELISA 20 h after setting up the co-culture.

[00320] None of the tested target cells were recognized by TCR + PD1-41BB-transduced CD8⁺ T cells (**Figure 8**). Only peptide-loaded target cells (positive controls) led to activation of T cells and consequent IFN-γ release. These results showed no signs of off-target toxicities caused by the recognition of endogenous peptides.

[00321] **Example 9: High and specific IFN-γ secretion in response to tumor cells.**

[00322] To be potentially useful in a clinical setting, it is essential that T cells expressing the candidate TCR are able to specifically recognize tumor cells expressing the target antigen. A standard way to assess tumor cell recognition by TCR-transgenic T cells is the evaluation of IFN-γ release by T cells upon target antigen-specific stimulation.

[00323] Tumor cell lines derived from various cancers (pancreatic, colorectal, lung and breast tumors) expressing mKRAS G12V at different levels (three homozygous cell lines and one heterozygous cell line) were selected as target cells for this co-culture experiment. In addition, two tumor cell lines expressing only KRAS wild-type served as mKRAS G12V-negative tumor target cells. All tumor cell lines were transduced with HLA-A*11:01-encoded molecules to allow surface expression of the desired HLA molecules. Expression of the transgenic HLA-A*11 molecules was confirmed by staining with anti-HLA-A11 antibody and subsequent flow cytometry analysis. To obtain robust and stable PDL1 expression, all selected tumor cell lines were transduced with PDL1. The interaction of PDL1 on tumor cells with PD1 on T cells usually leads to an inhibitory signal that reduces T cell activity. PD1-41BB CSR should reverse this signal and result in increased T cell reactivity when the transgenic TCR binds to its cognate peptide-HLA complex. Therefore, mKRAS G12V-positive tumor cell lines transduced with PDL1 served to evaluate maximum effect mediated by PD1-41BB CSR in an antigen specific manner. On the other hand, KRAS wild-type tumor cell lines transduced with PDL1 served as negative controls to ensure that PD1-41BB CSR did not negatively impact the specificity of the transgenic TCR-transduced T cells.

[00324] The co-culture experiment was set up by using the described tumor cell lines and TCR + PD1-41BB-transduced CD8⁺ T cells. Untransduced CD8⁺ T cells served as negative control. IFN-γ secretion was assessed 20 h after setting up the co-culture.

[00325] IFN-γ release was observed only when TCR + PD1-41BB-transduced CD8⁺ T cells were stimulated with mKRAS G12V-positive tumor cells (**Figure 9**). Highest IFN-γ release was observed for co-cultures with mKRAS G12V-positive tumor cells transduced with PDL1, showing the maximum effect of PD1-41BB CSR to transform in stimulation the natural inhibitory PDL1 signal for each tumor cell line. Importantly, no recognition of any KRAS wild-type tumor cells was observed. These findings confirmed the specificity of TCR + PD1-41BB

and its capacity to be activated and subsequently drive release of IFN in response to tumor cells expressing endogenous levels of mKRAS G12V. Additionally, they demonstrated that the specificity of the TCR-transgenic CD8⁺ T cells was not affected by PD1-41BB CSR co-expression.

[00326] Example 10: Strong and specific cytotoxic response against tumor cells even after multiple tumor challenges.

[00327] Tumor cell recognition by TCR-transgenic CD8⁺ T cells can be addressed not only by evaluating IFN- γ release upon target antigen-specific stimulation but also by testing cytotoxic response against tumor cells expressing the target tumor antigen.

[00328] To evaluate cytotoxic capacity of TCR + PD1-41BB-transduced CD8⁺ T cells, effector cells were co-cultured with tumor cell lines and monitored over time by a live-cell imaging system. The previous described tumor cell panel (four mKRAS G12V-positive and two KRAS wild-type cell lines) was used as target cells for this assay (both with and without PDL1 transduction). All tumor cells stably expressed a red fluorescent protein for tumor cell tracking by a live-cell imaging system. Cytotoxicity against tumor cells was determined by reduction in the absolute number of red fluorescent tumor cells over time.

[00329] Co-cultures containing TCR + PD1-41BB-transduced CD8⁺ T cells and mKRAS G12V-positive tumor cells showed decreasing absolute numbers of red fluorescent tumor cells, indicating robust and strong cytotoxic response mediated by TCR + PD1-41BB-transduced CD8⁺ T cells in response to tumor cell expressing endogenous levels of mKRAS₇₋₁₆ G12V epitope (**Figure 10A**). In contrast, proliferation and expansion of KRAS G12V-positive tumor cells were seen in co-cultures with the untransduced CD8⁺ T cells. Importantly, no reduction in numbers of KRAS wild-type tumor cells was observed in any co-cultures. These results showed the exclusive mKRAS G12V-specificity of TCR + PD1-41BB cytotoxic response.

[00330] To investigate T cell fitness and resilience, effector cells were co-cultured with 3-dimensional (3D) tumor cell spheroids and multiple challenges with fresh tumor cell spheroids were performed by transferring the tumor cells to the co-culture plates at different time points. These 3D tumor cell spheroids served as an in vitro model for solid tumors. Out of the previous described tumor cell panel, two mKRAS G12V-positive tumor cells were selected as target cells for this assay. These cell lines were tested both with and without PDL1 transduction. PDL1-transduced tumor cells served to further challenge T cells and to assess cytotoxic activity mediated by TCR + PD1-41BB-transduced CD8⁺ T cells in the presence of high levels of PDL1. All tumor cells expressed a red fluorescent protein for cell tracking over time. Cytotoxicity against tumor cell spheroids was determined by the reduction of red fluorescence signal over time using a live-cell imaging system.

[00331] Robust and strong cytotoxic response mediated by TCR + PD1-41BB-transduced CD8⁺ T cells was observed against mKRAS G12V-positive tumor cell spheroids. Importantly, cytotoxic activity mediated by TCR + PD1-41BB-transduced CD8⁺ T cells was maintained in the challenging environment with repeated exposure to tumor cells and in the presence of PDL1 overexpression (**Figure 10B**).

[00332] **Example 11: T cells co-expressing the transgenic TCR and PD1-41BB CSR showed a higher polyfunctionality compared to T cells expressing only the transgenic TCR.**

[00333] TCR-transgenic CD8⁺ T cells with or without PD1-41BB CSR were analyzed at single-cell level to evaluate polyfunctionality (release of 2 or more proteins) using the IsoLight® technology (PhenomeX). So called “polyfunctional” T cells can secrete multiple proteins (in particular cytokines and other effector proteins such as Gzm-B), thereby enabling a whole variety of effector functions and a highly effective immune response. After co-culture with the PDL1-overexpressing, mKRAS G12V-positive Dan-G_A11 tumor cell line for 24 h, single CD8⁺ T cells were separated from tumor cells using CD8 Microbeads (Miltenyi Biotec) and loaded onto IsoCode chips (PhenomeX). The secretion of 32 T cell cytokines/proteins was analyzed using the IsoLight® device and the IsoSpeak software (IsoPlexis). The poly-functional strength index (PSI) was calculated by multiplying the intensities of the various secreted proteins/cytokines and the percentage of polyfunctional T cells.

[00334] TCR-transduced T cells co- expressing PD1-41BB CSR showed a higher percentage of poly-functional T cells, meaning T cell secreting 2 or more proteins, compared to TCR-transduced T cells lacking PD1-41BB CSR (**Figure 11A**).

TCR + PD1-41BB-transduced T cells showed a higher polyfunctional strength index (PSI) compared to T cells expressing only the transgenic TCR (**Figure 11B**). Classification of the various cytokines/lytic proteins released revealed a high contribution of effector (Gzm-B, IFN- γ , MIP-1 α , Perforin, TNF- α , TNF- β) and stimulatory (GM-CSF, IL-5, IL-9) cytokines/lytic proteins to the superior PSI, followed by chemo-attractive (MIP-1 β , RANTES) cytokines. Regulatory cytokines (sCD137) were released only to a lower extent, while inflammatory cytokines were not released. Overall, these data point to a high T cell functionality and potential superior anti-tumor activity of T cells co-expressing the transgenic TCR and PD1-41BB CSR.

[00335] One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. Further, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The compositions, methods, procedures,

treatments, molecules and specific compounds described herein are presently representative of certain embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention are defined by the scope of the claims. The listing or discussion of a previously published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

[00336] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically disclosed herein. Thus, for example, the terms “comprising”, “including,” “containing”, etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by exemplary embodiments and optional features, modification and variation of the inventions embodied herein may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention.

[00337] The invention has been described broadly and generically herein. Each of the narrower species and sub-generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

[00338] Other embodiments are within the following claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

CLAIMS

1. A T-cell receptor (TCR) polypeptide complex and/or a combination comprising:
 - a) a TCR; and
 - b) a chimeric co-stimulatory receptor, preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising one or more PD-1-derived polypeptide and 4-1BB-derived polypeptide; further preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising a CD40L-derived polypeptide and a CD28-derived polypeptide;wherein the TCR comprises:
 - i) an α chain Complementarity Determining Region 1 (CDR 1) comprising the amino acid sequence of SEQ ID NO: 14; an α chain Complementarity Determining Region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 15; an α chain Complementarity Determining Region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 16; and
 - ii) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2; a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4,wherein the TCR has antigenic specificity to (an) epitope(s) presented in the context of a MHC class I molecule, the epitope comprising the amino acid sequence of VVVGAVGVGK (SEQ ID NO: 1) or a fragment thereof.
2. A cell population or a cell expressing:
 - a) a TCR; and
 - b) a chimeric co-stimulatory receptor, preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising one or more PD-1-derived polypeptide and 4-1BB-derived polypeptide; further preferably said chimeric co-stimulatory receptor is a fusion polypeptide comprising a CD40L-derived polypeptide and a CD28-derived polypeptide;wherein the TCR comprises:
 - i) an α chain Complementarity Determining Region 1 (CDR 1) comprising the amino acid sequence of SEQ ID NO: 14; an α chain Complementarity Determining Region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 15; an α chain Complementarity Determining Region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 16; and
 - ii) a β chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2; a β chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3; a β chain CDR3 comprising the amino acid sequence of SEQ ID NO: 4,

wherein the TCR has antigenic specificity to (an) epitope(s) presented in the context of a MHC class I molecule, the epitope comprising the amino acid sequence of VVVGAVGVGK (SEQ ID NO: 1) or a fragment thereof.

3. The complex and/or the combination, and/or the cell population or the cell of claim 1, wherein the TCR has antigenic specificity for said epitope(s) presented in the context of an HLA-A molecule.
4. The complex and/or the combination, and/or the cell population or the cell of claim 1, wherein the TCR has antigenic specificity for said epitope(s) presented in the context of an HLA-A*03 molecule.
5. The complex and/or the combination, and/or the cell population or the cell of claim 1, wherein the TCR has antigenic specificity for said epitope(s) presented in the context of an HLA-A*11 molecule, preferably in the context of at least any one of an HLA-A*11:01 molecule, an HLA-A*11:02 molecule, or an HLA-A*11:04 molecule.
6. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR comprises:
 - i) an α chain variable region comprising the amino acid sequence of SEQ ID NO: 20, or an amino acid sequence having at least 80 % identity to SEQ ID NO: 20; and/or
 - ii) a β chain variable region comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence having at least 80 % identity to SEQ ID NO: 8.
7. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR further comprises:
 - i) an α chain constant region comprising the amino acid sequence of SEQ ID NO: 22, or an amino acid sequence having at least 80 % identity to SEQ ID NO: 22; and/or
 - ii) a β chain constant region comprising the amino acid sequence of SEQ ID NO: 10, or an amino acid sequence having at least 80 % identity to SEQ ID NO: 10.
8. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR comprises:
 - i) an α chain comprising the amino acid sequence of SEQ ID NO: 24, or an amino acid sequence having at least 80 % identity to SEQ ID NO: 24; and/or

- ii) a β chain comprising the amino acid sequence of SEQ ID NO: 12, or an amino acid sequence having at least 80 % identity to SEQ ID NO: 12.
9. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR has antigenic specificity for said epitope(s) in the presence of the CD8 co-receptor.
10. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR is selected from the group consisting of a native TCR, a TCR variant, a TCR fragment, and a TCR construct.
11. The complex and/or the combination, and/or the cell population or the cell of claim 10, wherein the TCR construct comprises at least one TCR alpha-chain(s) and at least one TCR beta-chain(s) covalently linked to each other to form TCR heterodimers or multimers.
12. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, the TCR further comprising one or more fusion component(s) selected from the group consisting of a Fc receptor; a Fc domain, including IgA, IgD, IgG, IgE, and IgM; a cytokine, including IL-2 or IL-15; a toxin; an antibody or an antigen-binding fragment thereof, including anti-CD3, anti-CD28, anti-CD5, anti-CD 16 or an anti- CD56 antibody or an antigen-binding fragment thereof; and a CD247 (CD3-zeta), CD28, CD137, or a CD134 domain, or combinations thereof, optionally further comprising at least one linker.
13. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR further comprises at least one label.
14. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the TCR is soluble.
15. The complex and/or the combination, and/or the cell population or the cell of any one of the preceding claims, wherein the chimeric co-stimulatory receptor comprises:
- i) an extracellular domain, preferably comprising a polypeptide derived from PD-1, further preferably at its N-terminus;
 - ii) a transmembrane domain, preferably comprising a polypeptide derived from PD-1; and/or

- iii) an intracellular domain, preferably comprising a polypeptide derived from 4-1BB, further preferably at its C-terminus.
16. The complex and/or the combination, and/or the cell population or the cell of claim 15, wherein the transmembrane domain comprises a polypeptide derived from PD-1.
17. The complex and/or the combination, and/or the cell population or the cell of any one of claims 15-16, wherein
- i) said polypeptide derived from PD-1 comprised by said extracellular and/or by said transmembrane domain is a polypeptide derived from human PD-1; and/or
 - ii) said polypeptide derived from 4-1BB comprised by said intracellular domain is a polypeptide derived from human 4-1BB.
18. The complex and/or the combination, and/or the cell population or the cell of any one of claims 15-17, wherein
- i) said extracellular domain comprising a polypeptide derived from PD-1 comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions compared to SEQ ID NO: 28;
 - ii) said extracellular domain comprising a variant of the parent extracellular PD-1 polypeptide of SEQ ID NO: 28, wherein said variant comprises an alteration at one or more positions corresponding to positions of the parent polypeptide, wherein said variant has at least 80%, but less than 100% sequence identity to a parent amino acid sequence of SEQ ID NO: 28;
 - iii) said transmembrane domain comprising a polypeptide derived from PD-1 comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions compared to the amino acid sequence of SEQ ID NO: 30;
 - iv) said transmembrane domain comprising a variant of the parent PD-1 transmembrane polypeptide of SEQ ID NO: 30, wherein said variant comprises an alteration at one or more positions corresponding to positions of the parent polypeptide, wherein said variant has at least 80%, but less than 100% sequence identity to a parent amino acid sequence of SEQ ID NO: 30;
 - v) said intracellular domain comprising a polypeptide derived from 4-1BB comprises an amino acid sequence with 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions compared to SEQ ID NO: 32;
- and/or

- vi) said intracellular domain comprising a variant of the parent 4-1BB intracellular polypeptide of SEQ ID NO: 32, wherein said variant comprises an alteration at one or more positions corresponding to positions of the parent polypeptide, wherein said variant has at least 80%, but less than 100% sequence identity to a parent amino acid sequence of SEQ ID NO: 32.
19. The complex and/or the combination, and/or the cell population or the cell of any one of claims 15-18, wherein
- i) said extracellular domain comprises the amino acid sequence of SEQ ID NO: 28;
 - ii) said transmembrane domain comprises the amino acid sequence of SEQ ID NO: 30; and/or
 - iii) said intracellular domain comprises the amino acid sequence of SEQ ID NO: 32.
20. The complex and/or the combination, and/or the cell population or the cell of any one of claims 15-19, wherein said fusion protein comprises the amino acid sequence of SEQ ID NO: 26 or an amino acid sequence having at least 80% identity to SEQ ID NO: 26.
21. The cell population or the cell of any one of claims 2-20, wherein the cell is selected from lymphocytes including but not limited to cytotoxic T lymphocytes (CTLs), CD8⁺ T cells, CD4⁺ T cells, natural killer (NK) cells, natural killer T (NKT) cells, and gamma/delta-T-cells.
22. The cell population or the cell of any one of claims 2-21, wherein the cell population comprises cells which secrete at least two proteins or the cell secretes at least two proteins.
23. The cell population or the cell of claim 22, wherein the proteins are selected from the group consisting of effector proteins, stimulatory cytokines, chemo-attractive cytokines and regulatory cytokines.
24. The complex and/or the combination of any one of claims 1, 3-20, wherein the complex comprises a cellular membrane, wherein the TCR and the chimeric co-stimulatory receptor are located in or on said membrane.

25. A nucleic acid comprising a nucleotide sequence encoding the TCR as defined by any one of claims 1-20 and/or a nucleotide sequence encoding the chimeric co-stimulatory receptor as defined by any one of claims 1-20.
26. A vector comprising the nucleic acid of claim 25.
27. A host cell comprising the nucleic acid of claim 25, or the vector of claim 26.
28. A method for obtaining the TCR and the chimeric co-stimulatory receptor as defined by any one of claims 1-20, comprising
- (i) incubating the host cell of claim 27 under conditions causing expression of said TCR and of said chimeric co-stimulatory receptor; and
 - (ii) purifying said TCR and said chimeric co-stimulatory receptor.
29. A pharmaceutical or diagnostic composition comprising one or more of:
- (i) the complex and/or the combination of any one of claims 1, 3-20, 24;
 - (ii) the cell population or the cell of any one of claims 2-23,
 - (iii) the nucleic acid of claim 25;
 - (iv) the vector of claim 26; and/or
 - (v) the host cell of claim 27;
- and, optionally, pharmaceutically excipient(s).
30. The complex and/or the combination, and/or the cell population or the cell of any one of claims 1-24, the nucleic acid of claim 25, the vector of claim 26, the host cell of claim 27 and/or the pharmaceutical composition of claim 29 for use as a medicament and/or for use in therapy.
31. The complex and/or the combination, and/or the cell population or the cell of any one of claims 1-24, the nucleic acid of claim 25, the vector of claim 26, the host cell of claim 27 and/or the pharmaceutical composition of claim 29 for use in a method of detecting, diagnosing, prognosing, preventing and/or treating cancer.
32. The complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition for the use of claim 31, wherein prevention and/or treatment of cancer comprises:
- administering at least any one of the following (i) to (vi):
- (i) the complex and/or the combination of any one of claims 1, 3-20, 24;

- (ii) the cell population or the cell of any one of claims 2-23,
 - (iii) the nucleic acid of claim 25;
 - (iv) the vector of claim 26;
 - (v) the host cell of claim 27; and/or
 - (vi) the pharmaceutical composition of claim 29;
- to a subject in need thereof.
33. The complex and/or the combination, and/or the cell population or the cell, the nucleic acid, the vector, the host cell and/or the pharmaceutical composition for the use of claim 31, wherein prevention and/or treatment of cancer comprises:
- (a) introducing at least any one of the following (i) to (vi):
 - (i) the complex and/or the combination of any one of claims 1, 3-20, 24;
 - (ii) the cell population or the cell of any one of claims 2-23,
 - (iii) the nucleic acid of claim 25;
 - (iv) the vector of claim 26;
 - (v) the host cell of claim 27; and/or
 - (vi) the pharmaceutical composition of claim 29;into lymphocytes comprised by a sample obtained from a subject, thereby obtaining modified lymphocytes, and
 - (b) administering the modified lymphocytes of step (a) to a subject in need thereof.
34. A method of detecting the presence of a cancer in a subject *in vitro*, comprising:
- (a) contacting a sample obtained from a subject and comprising one or more cells with
 - (i) the complex and/or the combination of any one of claims 1, 3-20, 24;
 - (ii) the cell population or the cell of any one of claims 2-23,
 - (iii) the nucleic acid of claim 25;
 - (iv) the vector of claim 26;
 - (v) the host cell of claim 27; and/or
 - (vi) the pharmaceutical composition of claim 29;thereby forming a complex, and
 - (b) detecting the complex,
- wherein detection of the complex is indicative of the presence of the cancer in the subject.

35. Use of the complex and/or the combination, and/or the cell population or the cell of any one of claims 1-24, the nucleic acid of claim 25 and/or the vector of claim 26 for generating modified lymphocytes.
36. A kit comprising the complex and/or the combination, and/or the cell population or the cell of any one of claims 1-24, the nucleic acid of claim 25, the vector of claim 26, the host cell of claim 27, and/or the pharmaceutical or diagnostic composition of claim 29.